# Beta lactam compounds.

## Abstract
An amine compound of formula I or an amidine derivative thereof or a pharmaceutically acceptable salt or ester thereof

## Claims
CLAIMS 1 A compound of formula I or an amidine derivative thereof or a pharmaceutically acceptable salt or ester thereof EMI83.1 wherein Rm 1s hydrogen or a group OR, Rn is hydrogen or methyl, R is hydrogen, CHO or SO3H or a pharmaceutically acceptable salt thereof, R1 and R2 are independently hydrogen, C16 alkyl, or R1 and R2 are joined so as to form with the carbon to which they are attached a C37 cycloalkyl ring, and X1 and X2 are independently hydrogen or optionally substituted hydrocarbon. 2 A compound as claimed in claim 1 wherein X1 and X2 independently represent hydrogen, C1 6 alkyl or optionally substituted aryl. 3 A compound as claimed in either of claims 1 or 2 wherein Rm represents a group OR, and Rn represents hydrogen. 4 A compound as claimed in any one of claims 1 3 wherein R is hydrogen or CHO. 5 An amidine compound, as claimed in claim I , of formula II or a pharmaceutically acceptable salt or ester thereof EMI84.1 wherein Rm,Rn, R1, R2 X1 and X2 are as defined in claim 1 and R3, R4 and R5 are independently selected from hydrogen or an optionally substituted hydrocarbon or heterocyclic group or R4 and R5 together with the nitrogen to which they are attached form a 3 10 membered heterocyclic ring. 6 A compound as claimed in claim 5 wherein R3, R4 and R5 are independently hydrogen or C16 alkyl. 7 A compound selected from any of the following or a pharmaceutically acceptable salt or ester thereof 5R,6R 3 Z 3 aminoprOp l enylthl0 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R, 6S 3 Z 3 aminoprop 1 enylthio 6 R 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid SR,6R 3 3 aminobut l en l ylthlo 6 l S l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5R,6S 3 3 amlnobut l en l ylthlo 6 R l formyloxyethyl 7 oxo l azablcycloL3.2.0lhept 2 ene 2 carboxylic acid 5R,6R 3 l Z 3 acetlmidoylamlnoprop l enylthlo 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R,6R 3 l Z 3 formlmidoyl aminoprop l enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R,6S 3 3 amlnobut l en l ylthlo 6 l R l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5R,6R 3 l Z 3 amino l methylprop l enylthio3 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R, 6R 3 3 amino 1 phenylprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5R,6S 3 Z 3 amlno l methylprop l enylthio 6 R l hydroxyethyl 7 oxo l azabicyclo 3.2.0 hept 2 en e 2 carboxylic acid 5R, 6R 3 E 3 aminoprop 1 enylthio 6 S 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene car boxylic acid 5R, 6S 3 E 3 aminoprop 1 enylthio 6 R l hydroxyethyl 7 oxo l azablcyclol3.2.0 hept 2 ene 2 carboxylaic acid 5RS,6SR 3 l Z 3 amlnoprop l enylthlo 6 lRS 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 C arboxylic acid 5Rs, 6SR 3 E 3 amino 1 methylprop 1 enylthio 6 RS 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid 5Rt6R 3 l E 3 amlno l methylprop l enylthlol 6 lts l hydroxyethyl 7 oxo l azablcyclol3.2.0 hept 2 ene 2 carboxylic acid. 8 A process for the preparation of a compound as claimed in claim I which process comprises eitherA reacting a compound of formula III EMI87.1 wherein R1 and R2 are as defined ln claim 1, R9 ls hydrogen or a group ORP, where RP is a group R as defined ln claim 1 or a protected derivative thereof, Rx ls a carboxy protecting group and R is an optionally substituted hydrocarbon or heterocyclic group with a compound of formula IV or a salt or an amidine derivative thereof EMI87.2 where Y is amino, protected amino, or a precursor thereof or,B the elimination of the elements of RaRbRcP O from an ester of a compound of the formula V or an amidine derivative thereof EMI88.1 wherein Rn, XÚ, X2, R1 and R2 are as defined in claim 1, R9 is as defined with respect to formula III , Y is as defined with respect to formula IV and Ra, Rb andRc are independently phenyl or methoxyphenyl or,C the reduction of a compound of formula X EMI88.2 wherein R1, R2 and Rn are as defined ln claim 1 and R9 and Rx are as defined with respect to formula III and thereafter if necessary one or more of the following steps a removing any protecting and or blocking groups b treating with dilute alkali c reacting a compound of formula I or a protected derivative thereof with either a compound of formula VII1 or IX EMI89.1 wherein R3, R4 and R5 are as defined, R6 is C1 6 alkyl, Y is oxygen or sulphur, X is halogen or C16 alkoxy and Z is a salting ion d converting a product into a pharmaceutically acceptable salt or ester. 9 A compound of formula X EMI89.2 wherein R1, R2, and Rn are as defined in claim l R9 and Rx are as defined in claim 8. 10 A compound of formula XI EMI90.1 wherein R1, R2 and Rn are as defined in claim 1 R9 andRx are as defined in claim 8 and T represents a readily displaceable group. 11 A compound of formula XII EMI90.2 wherein RÚ, R2, Rn and X1 and X2 are as defined in claim l R2 and Rx are as defined ln claim 8. 12 A compound of formula XV EMI91.1 wherein R1, R2, Rn and X1 are as defined in claim 1 R9 and Rx are as defined ln claim 8 and X represents x2 as defined ln claim 1 or ORY where CO2RY represents an ester group RY is a hydrocarbon radical. 13 A pharmaceutical composition which comprises a compound of formula I and a pharmaceutically acceptable carrier. 14 A compound as claimed ln any one of claims 1 to 7 for use ln the treatment of antibacterial infections.

## Description
B LACTAM COMPOUNDS This invention relates to novel t3 lactam containing compounds, their preparation and their use, and in particular to a novel class of carbapenems.These compounds have antibacterial properties, and therefore are of use in the treatment of bacterial infections in humans and animals caused by a wide range of organisms. The present invention relates to an amine compound of formula I or an amidine derivative thereof or a pharmaceutically acceptable salt or ester thereof EMI1.1 wherein Rm is hydrogen or a group OR, Rn 1s hydrogen or methyl, R is hydrogen, CHO or SO3H or a pharmaceutically acceptable salt thereof, R1 and R2 are independently hydrogen, C16 alkyl, or R1 and R2 are joined so as to form with the carbon to which they are attached a C37 cycloalkyl ring, and X1 and X2 are independently hydroyen or optionally substituted hydrocarbon. Suitably R 1s S03H or a pharmaceutically acceptable salt thereof such as an alkali metal salt, for example the sodium or potassium salt. Preferably Rm represents a group OR, and Rn represents hydrogen. Preferably R 1s hydrogen or CHO. In particular, the amidine derivatives of this invention include compounds of formula Il or a pharmaceutically acceptable salt or ester thereof EMI2.1 wherein Rm,Rn, R1, R2, X1 and X2 are as defined with respect to formula I and R3, R4 and R5 are independently selected from hydrogen or an optionally substituted hydrocarbon or heterocyclic group or R4 and R5 together with the nitrogen to which they are attached form a 3 10 membered heterocyclic ring. Suitably R3, R4 and R5 are independently hydrogen or C16 alkyl. Preferably R3, R4 and R5 are independently hydrogen or methyl. Preferably X1 and X2 independently represent hydrogen, C16 alkyl or optionally substituted aryl. In particular X1 and x2 independently represent hydrogen, methyl or phenyl. The compounds wherein R is CHO are active in their own right but it is possible that they could be converted to compounds wherein R is hydrogen in vivo. Suitably R1 is hydrogen, methyl or ethyl.Suitably R2 is hydrogen, methyl or ethyl. PreferablyR1 and R2 are both hydrogen. Examples of suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salts, for example acyloxyalkyl groups, such as acetoxymethyl, pivaloyloxymethyl, c acetoxyethyl and oc pivaloyloxyethyl groups alkoxycarbonyloxyalkyl groups, such as ethoxycarbonyloxymethyl and O ethoxycarbonyloxyethyl dialkylaminoalkyl groups, such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl and lactone groups such as phthalidyl or dimethoxyphthalidyl. Suitable pharmaceutically acceptable salts of the compounds of formula I include metal salts, eg aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy lower alkylamines such as 2 hydroxyethylamine, bis 2 hydroxyethyl amine or tri 2 hydroxyethyl amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N benzyl phenethylamine, phenethyl amine, dehydroabrietylamine, N, N bisdehydroabietylamine, ethylenediamine, or bases of the pyridine type such as pyridine, collidine or quinoline. As used herein the term hydrocarbon includes groups having up to 18 carbon atoms, suitably up to 10 carbon atoms, conveniently up to 6 carbon atoms.Suitable hydrocarbon groups include Cl6 alkyl, C26 alkenyl, C26 alkynyl, C37 cycloalkyl, C37 cycloalkyl C1 6 alkyl, aryl, and aryl C1 6 alkyl. Suitable alkyl groups include straight and branched chain alkyl groups containing from 1 to 6 carbon atoms, such as methyl, ethyl, propyl and butyl.A particular alkyl group is methyl. The term heterocyclyl includes single or fused rings comprising up to four hetero atoms in the ring selected from oxygen, nitrogen and sulphur and optionally substituted with up to three halogen, C1 6 alkyl, C16 alkoxy, halo C1 6 alkyl, hydroxy, amino, carboxy, C1 6 alkoxycarbonyl, C1 6 alkoxycarbonyl C1 6 alkyl, aryl or oxo groups. Suitably the heterocyclic ring comprises from 4 to 7 ring atoms, preferably 5 to 6 atoms. When used herein the term aryl includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, C16 alkyl, phenyl, C1 6 alkoxy, halo C1 6 alkyl, hvdroxv, amino, nitro, carboxy, C16 alkoxycarbonyl, C16 alkoxycarbonyl C1,6 alkyl C1 6 alkylcarbonyloxy, or C1 6 alkylcarbonyl groups. Suitable optional substituents for the hydrocarbon, heterocyclic groups and organic radicals include C1 6 alkyl, heterocyclic, amino, C16 alkanoyl amino, mono, di and tri C1 6 alkylamino, hydroxy, C16 alkoxy, mercapto, C16 alkylthio, heterocyclyl thio, arylthio, sulphamoyl, carbamoyl, amidino, guanidino, nitro, chloro, bromo, fluoro, carboxy and salts and esters thereof, C16 alkanoyloxy, aryl carbonyl and heterocyclylcarbonyl. The compounds of this invention may have R or S stereochemistry at the C B position that is the alpha carbon atom of the C 6 substituent or may be in the form of mixtures thereof. The compounds of this invention may be provided with a cis configuration of the C 5 and C 6 protons, or they may be provided with a trans configuration of the C S and C 6 protons. Alternatively they are provided as a mixture of the cis and trans forms. Preferred configurations for the compounds of this invention with an asymmetric 8 position are 5R, 6R, 8s, and 5R, 6S, 8R. The double bond present in the C 3 thio substituent may be present in either the E configuration or the Z configuration, or the compounds may be provided as mixtures thereof. Preferably the double bond is in the Z or cis configuration. The compounds most suitably may be presented in the form of the carboxylic free acid at the C 2 position, said compounds preferably being in zwitterion form. Preferred compounds of this invention are compounds of formula I , wherein Rm is OH, and Rn, R1, and R2 are hydrogen 5R,6R 3 Z 3 amlnoprop l enylthlo 6 S l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid 5R, 6S 3 Z 3 aminoprop 1 enylthio 6 R 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5R, 6R 3 3 aminobut 1 en 1 ylthio 6 S 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5R, 6S 3 3 aminobut 1 en 1 ylthio 6 R 1formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5R,6R 3 Z 3 acetlmldoylamlnoprop l enylthlo 6 S 1 hydroxyethyl 7 oxo 1 zabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R,6R 3 Z 3 formlmldoyl amlnoprop l enylthlo3 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R, 6S 3 3 aminobut 1 en 1 ylthio 6 R 1 hydroxyethyl 7 oxo 1 azablcyclo 3.2.01hept 2 ene 2 carboxylic acid 5R, 6R 3 Z 3 amino 1 methylprop 1 enylthio 6 S l hydroxyethyl 7 oxo 1 azablcyclot3.2.0lhept 2 ene 2 carboxylic acid 5R, 6R 3 3 amino 1 phenylprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R, 6S 3 Z 3 amino 1 methylprop 1 enylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid 5R,6R 3 t E 3 aminoprop 1 enylthio 6 t S l hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5R, 6S 30 E 3 aminoprop 1 enylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid 5RS,6SR 3 Z 3 aminoprop 1 enylthio 6 lRS 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid 5Rs, 6SR 3 E 3 amino 1 methylprop 1 enylthio 6 RS 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid 5R, 6R 3 E 3 amino 1 methylprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid. The compounds of this invention may be prepared by a process which comprises reacting a compound of formula III EMI8.1 wherein R1 and R2 are as defined with respect to formu a I , RP is hydrogen or a group ORP, where RP is a group R as defined with respect to formula I or a protected derivative thereof, Rx is a carboxy protecting group and RO is an optionally substituted hydrocarbon or heterocyclic group with a compound of formula IV or a salt or an amidine derivative thereof EMI8.2 where Y is amino, protected amino, or a precursor thereof,and optionally thereafter removing any protecting groups and converting the product into a pharmaceutically acceptable salt or ester. Compounds of formula III may be prepared as described in European Patent Application PublicationNumbers 0,060,077 and 0,060,612. Suitable protected derivatives RP of the group R are those conventional in the art, for example groups cleavable by hydrolysis such as formate or silyl groups or groups cleavable by hydrogenation such as benzyloxycarbonyloxy and p nitrobenzyloxycarbonyloxy. Suitably Y is amino or protected amino. Suitable amino protecting groups are those well known in the art which may be removed under conventional conditions without disruption of the remainder of the molecule. Examples of N protecting groups include C16 alkanoyl, for example acetyl, propionyl n and isobutyryl and 2,2 dimethylpropanoyl, benzoyl or benzene optionally substituted in the phenyl ring by one or two substituents selected from C14 alkyl1 C14 alkoxy, trifluoromethyl, halogen or nitro and C14 alkoxycarbonyl, for example tert butoxycarbonyl or benzyl optionally substituted as for benzoyl above. Alternatively the group Y may be a precursor of an amino groups, such as hydroxy or azido. This reaction may be performed in any solvent that is substantially inert during the reaction, for example tetrahydrofuran, dimethyl formamide, dioxan, hexamethyl phosphoramide, dimethoxyethane or dimethoxydiethyl ether. Of these solvents dimethylformamide is preferred. Alternatively we have found it useful to use a phase transfer catalysts such as tetra n butyl ammonium bromide, cetyl benzyl dimethylammonium chloride and cetyltriethylammonium chloride suitable solvents include halogenated water immiscible solvents such as chloroform in the presence of water.The reaction is normally performed at ambient or a depressed temperature, for example 20µC to 70 C, and preferably between 0 C and SO0C. However, when using a phase transfer catalyst it is preferable to conduct the reaction between oec and ambient temperature. When the thiol of the formula IV is used the reaction is normally carried out in the presence of a base. Examples of such bases include sodium hydride, sodium hydroxide, sodium alkoxide such as the methoxide, ethoxide or butoxide, sodium amide, potassium hydroxide, potassium alkoxide such as the methoxide ethoxide or butoxide, potassium amide, and trialkyl amines such as triethylamine and tri n propylamine. Of these triethylamine is preferred. Preferably the base is present in an amount of at least 0.9 equivalents, more preferably between 1.0 and 1.2 equivalents per mole of the thiol compound. Instead of using a base in the reaction a reactive derivative of the thiol may be used, preferably the reactive derivative is a salt of the thiol, in particular an alkali metal salt such as sodium or potassium. The amount of thiol compound of the formula IV or reactive derivative is generally between 1.0 and 1.5 moles per mole equivalent of the compound of the formula III . Suitable carboxyl protecting derivatives for the group CO2RX in formula III include salts and ester derivatives of the carboxylic acid. The derivative is preferably one which may readily be cleaved at a later stage of the reaction. Suitable salts include metal salts, such as those with sodium, potassium and lithium, and tertiary amine salts, such as those with trllower alkylamlnes, N ethylplperidlne, 2,6 lutidine, pyridine, N methylpyrrolidine, dimethylpiperazine. A preferred salt is with triethylamine. Suitable ester forming carboxyl protecting groups are those which may be removed under conventional conditions. Such groups for Rx include benzyl, pmethoxybenzyl, 2,4,6 trimethylbenzyl, 3,5 dl t butyl4 hydroxy benzyl, benzoylmethyl, p nitrobenzyl, 4 pyridylmethyl, 2,2,2 trlchloroethyl, 2,2,2tribromoethyl, allyl, acetonyl, t butyl, t amyl. diphenylmethyl, triphenylmethyl, adamantyl, 2 benzyloxyphenyl, 4 methylthiophenyl, tetrahydrofur 2yl, tetrahydropyran 2 yl, pentachlorophenyl, p toluenesulphonylethyl, methoxymethyl, a silyl, stannyl or phosphorus contalnlng group, an oxime radlcal of formula N CHRO where RO is aryl or heterocyclic, or an in vivo hydrolysable ester radical. The carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular RX group, for example, acid and base catalysed hydrolysis, or by enzymically catalysed hydrolysis, or by hydrogenation. The compounds of this invention may also be prepared by a process which comprises the elimination of the elements of RaRbRCP 0 from an ester of a compound of the formula V or an amidine derivative thereof EMI11.1 wherein Rq, Rn, X1, X2, R1, R2 and Y are as herein before defined and Ra, Rb and RC are independently phenyl or methoxyphenyl and optionally thereafter removing any protecting and or blocking groups and converting the product into a pharmaceutically acceptable salt or ester. Suitably this process is performed by heating the ester of the compound of the formula V in an inert solvent, for example at temperatures of 90 C to 120 C and more suitably 1000C to llO C in a solvent such as toluene, preferably under substantially anhydrous conditions. The preparation of the compounds of the formula V may be effected by the reaction of a compound of the formula VI EMI12.1 wherein Rs, Rn, RI, R2, Rx, Ra, Rb and Rc are as hereinbefore defined with a di C1,6 alkylphosphoro chloridate or thionyl chloride and a tri C1 6 alkyl amine followed by reaction with a derivative of the formula VII EMI12.2 or an amidine derivative thereof, wherein X1, X2 and Y are as hereinbefore defined and L is a lithium, sodium, silver or thallium I cation or an ammonium ion substituted by up to three C16 alkyl groups. When L is a substituted ammonium ion, it as preferably a tertiary ammonium ion, such as the triethylammonium ion. Preferably L is a thallium I cation or a silver cation. A particularly suitable di oweralkylphosphoro chloride is diethylphosphorochloridate. A particularly suitable tri loweralkylamine 1s triethylamine. The reaction is generally carried out in an inert organic solvent such as tetrahydrofuran at a non extreme temperature such as 0 C to 40 C, for example 15 C et 25 c. The compounds of the formula VI may be prepared by the methods of European Patent ApplicationPublication Numbers 0008888, 0008514, 0002564 and 0060612. The amine compounds of formula I may be prepared by a process which comprises .e reaction of a compound of formula X EMI13.1 wherein R1, R2, Rq, Rn and Rx are as hereinbefore defined The reduction of compound X may be carried out by any conventional reduction methods such as by hydrogenation or the use of other reducing agents such as hydrogen sulphide triethylamine. The hydrogenation is normally carried out in the presence of a transition metal catalyst, such as palladium, for example in the form of palladium on carbon charcoal , palladium on barium sulphate, palladium on calcium carbonate, and palladium black. A favoured catalyst is palladium on carbon sometimes referred to as palladium on charcoal for example 5 , 10 , 20 or 30 palladium on carbon. A low, medium or high pressure of hydrogen may be used in this reaction, for example from 1 to 6 atmospheres. The reaction is normally carried out at a non extreme temperature, for example from OOC to 300C and more usually from 120C to 250C. It is generally convenient to carry out the reaction at ambient temperature.Suitable solvents for carrying out the hydrogenation include ethanol, n propanol, isopropanol, tetrahydrofuran, dioxan, ethyl acetate or mixtures of such solvents or such solvents in the presence of water. A favoured solvent is aqueous 1,4 dioxan, preferaly buffered to neutral pH. The compound of formula X may be prepared by reacting a compound of formula XI EMI15.1 wherein R1, R2, R9, Rn and Rx are as hereinbefore defined and T represents a readily displaceable group with an azide. Suitably the azide is an inorganic azide such as an alkali metal azide e.g. sodium azide or lithium azide or an organic azide such as tetramethylguanidium azide, or tetrabutylammonium azide. The readily displaceable group T may be for example a halogen atom e.g. chlorine, bromine or iodine or an acyloxy group such as an optionally substituted hydrocarbon carbonyloxy or sulphonyloxy group. Suitable such groups include dichloroacetoxy, methanesulphonyloxy, fluoromethanesulphonyloxy, ptoluenesulphonyloxy, p nltrobenenesulphonyloxy or trlfluoromethylsulphonyloxy. Compounds of formula XI wherein T is an acyloxy group may be prepared by reacting a hydroxy compound of formula XII with an appropriate acylating agent e.g.an acyl halide or anhydride. EMI16.1 Compounds of formula XI wherein T is halogen may be obtained by reaction of compound XII with a halogenating agent such as a thionyl halide. In a preferred method of preparing the compound of formula X , the intermediate activated derivative XI Is not isolated. In this aspect, the hydroxy compound XII is reacted with 1 a compound of formula XIII EMI16.2 wherein p, q and r are independently zero or 1 and Ra,Rb and Re are each independently C16 alkyl, aryl or aryl C1 6 alkyl 11 hydrazoic acid and 111 a compound of formula XIV RdO.CON NCO.ORe wherein Rd and Re are independently C1 6 alkyl, aryl or aryl Cl 6 alkyl. Suitable compounds of the formula XIII include those wherein the Ra, Rb and RC groups are selected from methyl, ethyl, n propyl, n butyl, benzyl, phenyl and methoxyphenyl groups. It is generally convenient that Ra, Rb and Rc each represent the same moiety.Favoured compounds of the formula XIII include tri aryl phosphines and tri alkylphosphites.Particularly suitable compounds of the formula XIII include triphenylphosphine, trimethylphosphite, trl ethyl phosphlte, trl p methoxyphenylphosphlne and trl n butylphosphlne. Suitable compounds of the formula XIV include those wherein Rd and Re are independently selected from methyl, ethyl, propyl , butyl, phenyl and benzyl groups. It is generally convenient that Rd and Re represent the same moiety. Particularly suitable compounds of the formula XIV include those wherein Rd and Re each represent a methyl, ethyl, t butyl or isopropyl group. Particular compounds of formula XIV include diethylazodicarboxylate and diisopropylazodicarboxylate. The reaction is performed in an inert organic solvent. The solvent used should be aprotic and substantially unreactive towards the reagents involved. Suitable solvents include tetrahydrofuran, dioxan, ethyl acetate, benzene, toluene and chlorobenzene. Of these tetrahydrofuran is preferred. The reaction is normally carried out at a nonextreme temperature such as 200C to lOOoC, more usually from about 5 C to 500C and conveniently at ambient temperature approximately 15 C to 250C . The hydroxy compound of formula XII may be prepared by reduction of a compound of formula XV EMI18.1 wherein X represents X2 or ORY where COWRY represents an ester group. Suitably RY is a hydrocarbon radical, such as C16 alkyl, preferably methyl or ethyl. A suitable method of reduction utilises a complex hydride such as a borohydride, for example lithium borohydride, sodium or potassium borohydride, sodium cyanoborohydride, di isobutyl aluminium hydride or a reagent such as aluminium tri isopropoxide. The preferred reducing agent is selected according to the nature of the compound XV , i.e. whether it is an aldehyde, ketone or ester. The reaction may be performed in an inert organic solvent such as a hydrocarbon, a chlorinated hydrocarbon or an ether, for example toluene, cyclohexane, diethyl ether, heptane, hexane, dichloromethane or tetrahydrofuran. The reaction may be performed at any non extreme temperature for example 300C to 6O0C, more suitably 200C to OOC. Compounds of formula XV are prepared as disclosed in European Patent AppZication Publication No 0,024,832. Compounds of formulae X , XI , XII and compounds XV where X represents X2 are novel compounds and form a further aspect of this invention. The amidine compounds of formula II may be prepared by a process which comprises reaction of a compound of formula I or a protected derivative thereof with either a compound of formula VIII or IX EMI19.1 wherein R3, R4 and R5 are as defined with respect to formula II , R6 is C16 alkyl, Y is oxygen or sulphur,X is halogen or C16 alkoxy and Z is a salting ion. The compound of the formula VIII is preferably used in the form of its acid addition salt, for example as the hydrochloride. Suitably R6 is a methyl or ethyl group. SuitablyY is an oxygen atom. Suitably also X is C1 6 alkoxy such as methoxy or ethoxy. Suitably Z is halo such as chloro, or is a tetrafluoroborate ion. Reaction of the compound of the formula I with either the compound of the formula VIII or IX is suitably performed in water, ether, dioxan, tetra hydrofuran, dimethylformamlde, dichloromethane or mixtures of such solvents. Suitably the reaction lsperformed between 0 C and ambient temperature. In aqueous media it has been found convenient to carry out the reaction at a basic pH, for example 7.5 to 10, preferably 8 to 9. The present invention also provides a pharmaceutical composition which comprises a compound of this invention and a pharmaceutically acceptable carrier. The compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of the infection in anials especially mammals including humans. Suitable forms of the compositions of this invention include tablets, capsules, creams, syrups, suspensions, solutions, reconstitutable powders and sterile forms suitable for injection or infusion. Such compositions may contain conventional pharmaceutically acceptable materials such as diluents, binders, colours, flavours, preservatives, disintegrant and the like in accordance with conventional pharmaceutical practice in the manner well understood by those skilled in the art of formulating antibiotics. The injectable solution of the compound of this invention may be made up in a sterile pyrogen free liquid such as water, aqueous ethanol or the like. Unit dose compositions comprising a compound of this invention adapted for oral administration form a further suitable composition aspect of this invention. The compositions may contain from 0.1 by weight, preferably from 10 60 by weight, of the active material, depending on the method of administration.Where the composition comprise dosage units, each unit will preferably contain from 50 500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg kg per day. Suitably the dosage is from 5 to 20 mg kg per day. The compound of the formula may be present in the composition as sole therapeutic agent or it may be present together with other therapeutic agents such as, for example, a penicillin or cephalosporin.Considerable advantages accrue from the inclusion of a penicillin or cephalosporin which shows instability to D lactamases since the resulting composition shows enhanced effectiveness synergy . Suitable penicillins, cephalosporins or other 7 lactam antibiotics for inclusion in such synergistic compositions include not only those known to be highly susceptible to lactamases but also those which have a degree of intrinsic resistance to B lactamases. Suitable penicillins for inclusion in the compositions of this invention include benzylpenlclllln, phenoxymethylpenicillin, carbenicillin, azidocillin, propicillin, ampicillin, amoxycillin, epicillin, ticarcillin, cyclacillin, pirbenicillin, azlocillin, mezlocillin, sulbenicillin, pipericillin, and other well known penicillins including pro drugs thereof such as their in vivo hydrolysble esters such as the acetoxymethyl, pivaloyloxymethyl, O ethoxycarbonyloxyethyl or phthalidyl esters of ampicillin benzylpenicillin or amoxycillin, and aldehyde or ketone adducts of penicillins containing a 6 oC aminoacetamide side chain such as hetacillin, metampicillin and analogous derivatives of amoxycillin or esters of carbenicillin or ticarcillin such as their phenyl or indanyl C esters. Suitable cephalosporins for inclusion in the compositions of this invention include, for example, cefatrizine, cephaloridine, cephalothin, cefazolin, cephalexin, cephacetrile, cephapirin, cephamandole nafate, cephradine, 4 hydroxycephalexin, cefaparole, cephaloglycin, cefoperazone, and other well known cephalosporins or pro drugs thereof. When present together with a cephalosporin or penicillin, the ratio of a compound of the invention to the penicillin or cephalosporin agent may vary over a wide range of ratios, such as from 10 1 to 1 10, for example about 3 1, 2 1, 1 1, 1 2, 1 3, 1 4, 1 5 or 1 6 wt wt, based on pure free antibiotic equivalent . The antibiotic compounds of the present invention are active against a wide range of gram negative and gram positive organisms. The MIC data included in the following examples is representative of the activity of the compounds of the present invention. The following Examples illustrate this invention. Preparation 1 p Nitrobenzyl 5R, 6R 3 Z 2 ethoxycarbonylethenyl thlo 6 l S l trlmethylsllyloxyethyl 7 oxo l aza blcyclo 3.2.01hept 2 ene 2 carboxylate p Nltrobenzyl 5R,6R 3 Z 2 ethoxycarbonyl ethenylthlol 6 S l hydroxyethyl 7 oxo l azablcyclo 3.2.0 hept 2 ene 2 carboxylate 0.757 gm el was dissolved in dry pyridine 5 ml and stirred at room temperature for 30 minutes with trimethylsilyl chloride 1.068 gm . The solvent was then evaporated at reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulphate and evaporated at reduced pressure. The crude product was chromatographed over silica gel 30 gm .Elution with 75 ethyl acetate hexane afforded the title compound as a pale yellow oil, which crystallised on standing 0.666 gm . gamma max CHC13 1782, 1708, 1608, 1580, 1559, 1521, 842 cm 1.Preparation 2 p Nitrobenzyl 5R, 6R 3 Z 3 ydroxyprop 1 enylthiol 6 1 S l trlmethylsllyloxyethyl 7 oxo l azablcyclo 3.2.0 hept 2 ene 2 carboxylate The ester p Nltrobenzyl SR,6R 3 2 2 ethoxycarbonylethenylthlo 6 S l trlmethyl Silyloxyethyl 7 oxo 1 aza bicclo 3.2.0 hept 2 ene 2 carboxylate 0.360 gm was dissolved in dry tetrahydrofuran 30 ml and cooled to OOC under an atmosphere of argon, with stirring. A solution of dilsobutylaluminium hydride in toluene 25 w v 1.15 ml, 2.02 mH was added and stirring was continued for 1.5 hours. The reaction was quenched by the addition of aqueous ethanol and the solution partitioned between ethyl acetate and water and filtered.The organic layer was washed with water, raturated sodium chloride solution, dried over magnesium sulphate and evaporated at reduced pressure.The residue was chromatographed over silica gel.Elution with 50 ethyl acetate hexane afforded initially unreacted starting material 0.040 gm .Continued elution with 50E ethyl acetate hexane gave the title compound 0.100 gm . gamma max EtOH 323, 264 nm, max CHC13 3600, 1782, 1701, 1609, 1559, 1521, 841 cm l Preparation 3 p Nltrobenzyl 5R,6R 3 Z 3 2zldoprop l enylthlol 6 S l trlmethylsllyloxyethyl 7 oxo l azablcyclo 3.2.0 hept 2 ene 2 carboxylate p Nitrobenzyl 5R, 6R 3 Z 3 hydroxyprop 1 enyl thlo 6 S l trlmethylsllyloxyethyl 7 oxo l aza bicyclo 3.2.0 hept 2 ene 2 carboxylate 0.078 gm was dissolved in dry tetrahydrofuran 25 ml and cooled to 0 C.Triphenylphosphine 0.137 gm , hydrazoic acid tl.70 M solution in toluene 0.3 ml and dilsopropyl azodlcarboxylate 0.106 gm were added to the solution, which was stirred at room temperature for 2.25 hours. The solution was partitioned between ethyl acetate and water. The organic layer was washed with sodium bicarbonate solution, saturated sodium chloride solution, dried over anhydrous magnesium sulphate and evaporated at reduced pressure.The crude product was chromatographed over silica gel 20 gin . Elution with 408 ethyl acetate hexane afforded the title compound as a pale yellow oil 0.041 gm , gamma max EtOH 322 nm, 263 nm, max CHCl3 2100, 1783, 1704, 1562, 1521, 842 cm, H CDC13 1.22 3H, d, CH3CH , 2.93 lH, dd, 4 Ha , 3.4 4.0 4H, m, 4 Hb CH2N3 , 4.05 4.4 2H, m, 5 H 8 H , 5.28 2H, q, CH2Ar , 5.89 1H, dt,C CHCH2N3 , 6.45 1H, d, SCH C , 7.55 2H, d, aromatic , 8.11 213, d, aromatic . Example 1 5R, 6R 3 Z 3 aminoprop 1 enylthio 6 S 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid p Nitrobenzyl 5R, 6R 3 azidoprop 1 enylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 20 mg was dissolved in 1,4 dioxan 9 ml , water 2 ml and pH 7.0 0.05M phosphate buffer 3 ml and shaken at ambient temperature and pressure for 1 hour 25 minutes in the presence of hydrogen and 5 palladium on carbon catalyst 30 mg . The suspension was filtered overCelite, washing well with water 20 ml . The filtrate was concentrated to approximately 20 ml by evaporation at reduced pressure and washed with ethyl acetate 3 x 50 ml .The pH of the aqueous solution was adjusted to 2.5 by the addition of dilute hydrochloric acid and immediately neutralised by the addition of dilute sodium hydroxide solution. The aqueous solution was concentrated to small volume at reduced pressure and chromatographed over HP 20. Elution with water afforded an aqueous solution containing the title compound estimated to contain 1.1 mg based on Elsooo at Xmax 301 nm in ultra violet spectrum . MIC against E. coli JT39 0.4 pg ml Pseudomonas aeruginosa A 6.2 pg ml. Preparation 4 p Nitrobenzyl 5R,6S 3 Z 2 methoxycarbonylethenyl thio 5 R 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate The title compound was prepared in quantitative yield by reaction of p Nitrobenzyl 5R, 6S 3 Z 2 methoxycarbonylethenylthlo 6 r R hydroxyethyll 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate with trimethylsilyl chloride in pyridine by the procedure outlined in preparation 1,9 max CHCl3 1780, 1705, 1602, 1590, 1550, 1520 and 841 cm 1.Preparation 5 p Nitrobenzyl 5R, 6S 3 Z 3 hydroxyprop 1 enylthio 6 R 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate The title compound was prepared in 8 yield by diisobutyl aluminium hydride reduction of p nitrobenzyl 5R, 6S 3 Z 2 methoxycarbonylethenylthio 6 R 1triemthylsilyoxyehtyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate, following the procedure outline in preparation 2, max CHCl3 1778, 1700, 1603, 1550, 1520 and 842, mas CH3CN 324 nm, 266 nm, H CDCl3 , 0.15 9H, s, SiMe3 , 1.28 3H, d, MeCH , 3.0 3.17 1H, dd, J 8Hz and 18Hz, 4 Ha , 3.18 1H, dd, J 3Hz and 6.5Hz, 6 H , 3.24 3.37 1H, dd, J 10Hz and 18Hz, 4 Hb , 4.2 4.28 2H, m, 5 H 8 H , 4.37 2H, d, J 6H4,CH2OH , 5.39 2H, ABq, CH2Ar , 6.09 lH, dt, J 6Hz and 10.0Hz, SCH CH , 6.34 1H, dt, J 10Hz and ca. 1Hz , 7.66 2H, d, aromatic , 8.22 2H, d, aromatic . Preparation 6 p Nitrobenzyl 5R, 6S 3 Z 3 azidoprop 1 enylthio 6 E R l trimethylsilyloxyethyl 7 OxO l aZabicyclo 3.2.0 hept 2 ene 2 carboxylate Reaction of p nitrobenzyl 5R, 6S 3 Z 3 hydroxyprop 1 enylthio 6 R 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylate with triphenylphosphine, diisopropylazodicarboxylate and hydrazoic acid, as described in preparation 3, afforded the title compound in 56 yield, max CHCl3 2100, 1780, 1700, 1603, 1559, 1520 and 841 cm1, Xmax CH3CN 322,264 nm, H CDC13 , 0.15 9H, s, SiMe3 , 1.28 3H, d, MeCH , 3.02 3.16 1H, dd, J 8.3Hz and 18.OHz, 4Ha , 3.20 1H, dd, J 2.8 and 6.5Hz, 6 H , 3.23 3.40 1H, dd, J 10.0 and 18.0Hz, 4 Hb , 4.03 2H, d, CH,N3 , 4.13 4.30 2H, m, 5 H 8H , 5.41 2H, ABq, CH2Ar , 5.98 1H, dt, J 6.5Hz and 9.5Hz, SCH CH , 6.54 1H, dt, J 1Hz and 9.5Hz, SCH CH , 7.67 2H, d, aromatics , 8.22 2H, d, aromatics .Example 2 5R, 6S 3 Z 3 aminoprop 1 enylthio 6 R 1 hydroxy ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid Hydrogenolysis and hydrolysis of p nitrobenzyl 5R, 6S 3 Z 3 azidoprop 1 enylthio 6 R 1trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate by the procedure described inExample 1 afforded an aqueous solution containing the title compound, max H20 301 nm. Preparation 7 p Nitrobenzyl 5R, 6R 3 Z 3 oxobut 1 en lylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate and the 3 E isomer A solution of p nitrobenzyl 5R,6R 3 E 2 acetamldoethenylthlo 6 S l hydroxyethyl 7 oXo l azablcyclo 3.2.0 hept 2 ene 2 carboxylate 200 mg in 15 aqueous dioxan 11.5 ml was stirred with N bromoacetamide 62 mg for 5 min. Chloroform was added and the organic solution was washed with water and dilute brine. The solution was dried MgSO4 and evaporated in vacuo to afford a foam which was dissolved in DMF 5 ml . To the solution was added K2C03 62 mg and but 3 yn 2 one 61 mg and the mixture was stirred for 25 min. Ethyl acetate was added and the solution was washed with water x 5 and brine.Evaporation of the dried mgSO4 organic layer gave a crude product which was chromatographed on silica gel employing a gradient elution of 30 hexane ethyl acetate to 100 ethyl acetate. First eluted was the E isomer of the title compound 20 mg m.p. 159 1620C from CH2Cl2 Et2O , max MeCN 335 20,766 and 264 nm 12, 395 max. KBr 1780, 1697 and 1678 cm 1 S DMF d7 1.33 3H, d,J 6.5 Hz, MeCH , 2.30 3H, s, MeCO , 3.62 1H, dd, J 10 and 18 Hz, 4 CHa , 3.74 1H, dd, J 6 and 9.5 Hz, 6 CH , 3.76 H, dd, J 8.5 and 18 Hz, 4 CH6 , 4.18 1H, m,CHMe , 4.46 1H, m, 5 CH , 5.22 lH, br, OH , 5.43 and 5.60 each 1H, d, J 14 Hz, CH2Ar , 6.55 1H, d, J 16Hz, CH.CO , 7.85 and 8.32 each 2H, d, J 8.5 Hz, C6H4 N02 1 and 8.03 1H, d, J 16 Hz, CHS . Found C, 55.5 H, 4.6 N, 6.45 M , 432.1022 C20H20N207S requires C, 55.55 H, 4.65 N, 6.5 , M, 432.0991 . Further elution gave the title Z isomer 56 mg m.p. 138 141 from CH2Cl2 Et2O max MeCN 340 19,142 and 264 nm 11, 767 max. KBr 1780, 1705, 1680 and 1665 cm 1, DMF d7 1.33 3H, d, J 6.5 Hz,MeCH , 2.27 3H, s, MeCO , 3.56 1H, dd, J 10 and 18Hz, 4 CHa , 3.72 1H, dd, J 6 and 9.5 Hz, 6 CH , 3.73 1H, dd, J 9 and 18 Hz, 4 CHb , 4.18 1H, m, CHMe , 4.43 1H, m, 5 CH , 5.18 1H, br, OH , 5.43 and 5.60 each 1H, d, J 14 Hz, CH2Ar , 6.66 1H, d, J 10 Hz, CHCO , 7.70 1H, d, J 10 Hz, CHS , 7.89 and 8.32 each 2H, d, J 9 Hz, CH2C6H4 NO2 Found C, 55.3 H, 4.7 N, 6.15 M , 432.1013 C20H20N207S requires C, 55.55 H, 4.65 N, 6.5 M, 432.0991 .Preparation 8 p Nltrobenzyl 5R,6R 3 Z 3 oxobut l en l ylthlo 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0Jhept 2 ene 2 carboxylate p Nitrobenzyl 5R, 6R 3 Z 3 oxo but 1 n 1 ylthio 6 S l hydroxyethyl 7 oxo 1 azablcyclo 3.2.0 hept 2 ene 2 carboxylate 300 mg was treated with trimethylsilyl chloride 0.26 ml in pyridine 3 ml as described in Preparation 1.The title product was obtained as a solid 228 mg m.p. 163 1650C from ethyl acetate Et2O max. MeCN 343 22,050 , and 265 nm 13, 625 max CH2C12 1785, 1710 cm 1 CDC13 0.09 9H, s, Me3Si , 1.34 3H, d, J 6.5Hz, MeCH , 2.29 3H, s, MeCO , 3.17 1H, dd, J 10.5 and 17.5 Hz, 4 CHa , 3.63 1H, overlapping dd, J 6 and 6Hz, 6 CH , 3.91 1H, dd, J 8.5 and 17.5 Hz, 4 CHb , 4.34 2H, m, 5 CH and CHMe , 5.33 and 5.52 each 1H, d,J 13.5 Hz, CH2Ar , 6.46 1H, d, J 10 Hz, CHCO , 7.22 1H, d, J 10 Hz, CHS , 7.2 and 8.25 each 2H, d, J 9Hz, C6H4 NO2 Found C, 54.5 H, 5.7 N, 5.6 M , 504.1359. C23H28N2O75Si requires C, 54.75 H, 5.6 N, 5.55 M, 504.1386 . Preparation 9 p Nitrobenzyl 5R, 6R0 3 hydroxybut 1 en 1 ylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo I3.2.01hept 2 ene 2 carboxylate A solution of p Nltrobenzyl SR,6R 3 Z 3 oxo but l en l ylthlo 6 t S l trlmethylsllyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 170 mg in THF 10 ml was cooled to 20 and a solution of sodium borohydride 40 mg in water 1 ml was added. The solution was stirred at 20 and when all the starting material had been consumed by t.l.c. ca. 45 min ethyl acetate was added. The solution was washed with water and brine, then dried MgSO4 and evaporated in vacuo.Chromatography of the crude product on silica gel using a gradient elution of 30 508 hexane in ethyl acetate afforded the title compound as a clear oil 83 mg max EtOH 325 and 265 nm max. CH2C12 3580, 1780 and 1700 cm,l, Preparation 10 p Nltrobenzyl 5R,6R 3 3 azldobut l en l ylthlo 6 S l trlmethylsllyloxyethyl 7 oxo l azablcyclo 13.2.0 hept 2 ene 2 carboxylate p Nitrobenzyl 5R, 6R0 3 3 hydroxybut 1 en 1ylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate 105 mg was allowed to react with triphenylphosphine, dl lsopropylazodlcarboxylate and hydrazoic acid in THF as described in Preparation 3. After 30 minutes the reaction was complete, and work up and chromatography again in the manner of Preparation 3 afforded the title azido derivative 41 mg Xmax. EtOH 324 and 264 nm max. CH2C12 2110, 1785 and 1705 cm 1. Preparation 11 p Nitrobenzyl 5R, 6S 3 Z oxo but 1 en 1 ylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate Using the methodology of preparation 7, Nitro benzyl 5R,6S 3 E 2 acetamldoethenylthlo 6 R l formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylate 300 mg was treated successively withN bromoacetamide and but 3 yn 2 one to furnish the title ketone 80 mg m.p. 151 154 from ethyl acetate hexane max. MeCN 342 18964 and 265 nm 11, 467 max. KBr 1780, 1720 1710 and 1665 cm 1 DMF d7 1.40 3H, d, J 6 Hz, MeCH , 2.27 3H, s,MeCH , 2.27 3H, s, MeCO , ca. 3.55 1H, m, 4 CHa , 3.73 1H, dd, J 10 and 18 Hz, 4 CHb , 3.94 1H, dd, J 3 and 6 Hz, 6 CH , 4.42 1H, m, 5 CH , 5.39 1H, m,CHMe , 5.45 and 5.62 each 1H, d, J 14 Hz, CH2Ar , 6.66 1H, d, J 10 Hz, CHCO , 7.65 1H, d, J 10 Hz, CHS , 7.89 and 8.32 each 2H, d, J 9 Hz, C6H4 N02 , 8.35 1H, s, OCHO Found C, 54.6 H, 4.3 N, 6.0 . C21H20H208S requires C, 54.8 H, 4.35 N, 6.1 .Preparation 12 p Nitrobenzyl 5R, 6S0 3 3 hydroxybut 1 en 1 ylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate The reduction of Nitrobenzyl 5R, 6S0 3 Z 3 oXobut l en l ylth1o 6 R l formuloxyethyll 7 oXo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 500 mg with sodium borohydride was accomplished by the method described in Preparation 9.The title hydroxy compound was obtained as a yellow foam 131 mg max. EtOH 324 and 266 nm max. CH2C12 3600, 1790, 1725 and 1710sh cm 1 CDCl3 1.29 3H, d, J 7 Hz, MeCH.C , 1.45 3H, d, J 6.5 Hz, MeCHO , 2.03 1H, br, OH , ca. 3.12 1H, dd, J 8.5 and 18 Hz, 4 CHa , 3.34 1H, ad, J 10 and 18 Hz, 4 CHb , 3.40 1H, dd, J 3 and 7 Hz, 6 CH , 4.23 1H, m, 5 CH , 4.82 1H, m, MeCHC , 5.26 and 5.52 each 1H, d, J 13.5 Hz, CH2Ar , 5.41 1H, m, MeCHO , 5.96 1H, dd, J 9 and 8 Hz, CH.CH , 6.2 1H, d, J 9 Hz, SCH , 7.66 and 8.23 each 2H, d, J 9 Hz, C6H4 N02 and 8.06 1H, d, OCHO .Preparation 13 p Nitrobenzyl 5R, 6S 3 3 azidobut 1 en 1 ylthio 6 1 R l formyloxyethyll 7 oxo 1 azablcyclot3.2.0j hept 2 ene 2 carboxylate The reaction of p Nitrobenzyl t5R,6S 3 3 hydroxybut l en l ylth1o 6 R l formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 180 mg with hydrazoic acid, triphenylphosphine and di isopropylazodicarboxylate was performed as inPreparation 3. Work up after 15 minutes followed by chromatography on silica gel using 30 60 ethylacetate in hexane to elute gave a partially purified product which was rechromatographed using chloroform to elute to afford the title azide as an oil 30 mg max. EtOH 321 and 264 nm. max. CH2C12 1790, 1730 and 1705sh cm 2.Example 3 5R,6R 3 3 Amlnobut l en l ylthlO 6 S l hydroxy ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid Following the procedure in Example 1, Nitro bonzyl 5R, 6R 3 3 Azidobut 1 en 1 ylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 70 mg was converted into the title amino acid max. H2O 301 nm. Example 4 5R,6S 3 3 Aminobut l en l ylthio 6 R l formyloxy ethyll 7 oxo 1 azablcyclo 3.2.0 hept 2 ene 2 carboxyllc acid p Nitrobenzyl 5R, 6S 3 3 azidobut 1 en 1 ylthlo 6 R l formyloxyethyl 7 oxo l azablcyclo 3.2.0 het 2 ene 2 carboxylate 20 mg was shaken with hydrogen and 5 Pd C in a mixture of dioxan 10 ml and 0.05 M pH 7 phosphate buffer solution 5 ml . After 2.5 h the mixture was filtered over Celite, washing with water, and the aqueous solution then washed x3 with ethyl acetate. Concentration of the aqueous solution followed by chromatography on Dragon HP20 eluting with water and 10 ethanol water afforded an aqueous solution of the title amino acid Xmax. H20 301 nm.Example 5 5R,6R 3 Z 3 Acetlmldoylamlnoprop l enylthlo 6 S l hydroxyethyl 7 oxo l azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid An aqueous solution of 5R,6R 3 t Z 3 amlnoprop l enylthlo 6 S l hydroxyethyl 7 oxo l azablcyclo 3.2.0 hept 2 ene 2 carboxylic acid 12 mg in 5 ml was cooled in an ice bath with stirring. The pH of the solution was adjusted to 9.0 by the addition of dilute sodium hydroxide solution. Ethyl acetimidate hydrochloride 101 mg was added portionwise over a period of 5 minutes, whilst maintaining the pH of the solution at 9.0. Stirring was continued for 30 minutes. The pH of the solution was then readjusted to 7.0 by the addition of dilute hydrochloric acid and chromatographed over HP 20, eluting with a gradient of 0 10 ethanol water.The fractions were monitored by u.v.spectroscopy and h.p.l.c. Those fractions containing the title compound were combined and lyophilised to yield a white solid,max. H20 302 nm, vmax. KBr 3300 broad , 1750, 1685, 1640, 1585 cm 1.Example 6 5R, 6R 3 Z 3 Formimidoylaminoprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid The title compound was prepared as a white solid by reaction of 5R, 6R 3 Z 3 aminoprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept2 ene 2 carboxylic acid see Example 1 with ethyl formimidate hydrochloride, by the procedure described in Example S,max H20 303 nm. Example 7 5R,6S 3 3 Aminobut l en l ylthlo 6 t hydroxy ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid An aqueous solution of SR,6S 3 3 aminobut l en1 ylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclol3.2.0 hept 2 ene 2 carboxylic acid was prepared as in Example 4. The pH of the solution was adjusted to 8.5 with 0.1N NaOH, and the solution maintained at this pH at 370C for 2 h. The solution was neutralised to pH7 with 0.1N HC1 and concentrated to small volume 10 ml , before loading onto a column of Diaion HP 20. Elution with water, followed by 5 ethanol water afforded an aqueous solution of the title amino acid max H2O 304 nm. Preparation 14 p Nitrobenzyl 5R, 6R 3 Z 3 oxo 1 methylprop 1 enylthio 6 S 1 hydoxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylateA. 2 Butyn l ol 1.0 gm was dissolved in dry N,Ndimethylformamide 20 ml and stirred vigourously for 16 hours at room temperature with Attenburrow manganese dioxide 5 gm . After removal of the manganese dioxide by centrifuging, the crude solution of 2 butyn l al was used in the next step.B. p Nltrobenzyl 5R,6R 3 E 2 acetamldovlnyl thlol 6 S l hydroxyethyl3 7 oxo l azablcyclo 3.2.0 hept 2 ene 2 carboxylate 0.250 gm was dissolved in 1,4 dioxan 10 ml containing water 15 drops . A solution of N bromoacetamide 0.078 gm in 1,4 dioxan 5 ml was added and the solution was stirred at room temperature for 5 minutes. Chloroform 100 ml was added and the organic solution washed with pH 7.0 phosphate buffer, brine and dried over MgS04. Removal of the solvent at reduced pressure afforded the crudeC 3 thiol as a colourless oil. This oil was dissolved in the solution of but 2 yn l al in N,N dimethylformamide obtained from part A. Anhydrous potassium carbonate 0.039 gm was added and the solution stirred at room temperature for 20 min.The solution was then partitioned between ethyl acetate and brine. The organic layer was dried over MgS04 and the solvent removed at reduced pressure to afford the crude product, which was chromatographed over silica gel 20 gm . Elution with 80 ethyl acetate hexane gave a mixture of p nltrobenzyl 5R,6R 3 Z 3 oxo 1 methyl prop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicy clo 3.2.0 hept 2 ene 2 carboxylate and the corresponding E isomer in the approximate ratio of 5 1, as a pale yellow gum 0.159 gm , max CHC13 3450, 1785, 1720, 1681, 1612, 1563 and 1523 cm 1 max EtOH 317, 264 nm S H CDC13 1.40 3H, d, J 6.5Hz, Wn3th t 2.32 major and 2.46 minor 3H, d, J 1 Hz,CH3C C , 2.9 3.2 1H, 2 x dd, major and minor isomers, 4 Ha , 3.45 3.75 2H, dd m, 4 Hb 6 H , 4.15 4.50 2H, m, 5 H 8 H , 5.28 5.51 2H, 2 x d, CH2Ar , 6.36 major isomer 6.00 minor isomer 1H, dd, J 1Hz and 7Hz, C CH , 7.64 2H, d, aromatic protons , 8.24 2H, d, aromatic protons , 10.08 major isomer and 9.83 minor isomer 1H, d, J 7Hz, CHO .Preparation 15 p Nitrobenzyl 5R, 6R 3 Z 3 oxo 1 methylprop 1 enylthio 6 S trimethylsilyloxyethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate The mixture of nitrobenzyl 5R, 6R0 3 Z 3 oxo l methylprop l enylthlo3 6 S l hydroxyethyl 7 oXo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate and the corresponding E isomer 0.130 gm was dissolved in pyridine 2 ml and stirred at room temperature for one hour with trimethylsilyl chloride 0.196 gm . The solvent was then evaporated at reduced pressure and the residue partitioned between ethyl acetate and water.The organic layer was washed with brine, dried over anhydrous magnesium sulphate and evaporated at reduced pressure to yield the crude product, which was chromatographed over silica gel. Elution with 1 1 ethyl acetate hexane afforded p nitrobenzyl 5R, 6R 3 Z 3 oxo 1 methylprop 1 enylthio 6 S l trlmethylsllyloxyethyl3 7 oxo l azablcyclo 3.2.03 hept 2 ene 2 carboxylate, sllghtly contaminated with the E isomer 0.093 gm ,V max CHC13 1788, 1722, 1678, 1610, 1562, 1522, 842 cm 1 max EtOH 318, 263 nm, H CDC13 0.11 9H, s, Me3 , 1.31 3H, s, J 6.5Hz, CH3CH , 2.29 major isomer and 2.46 minor isomer 3H, d, J ca. 1Hz, CH3C C , 2.65 3.25 1H, m, 4 Ha , 3.45 3.95 2H, m, 4 Hb 6 H , 4.1 4.5 2H, m, 5 H 8 H , 5.26 5.52 2H, 2 x d, CH2Ar , 6.34 major 5 96 minor isomer 1H, broad d, C CH , 7.64 2H, d, aromatic H , 8.20 2H, d, aromatic H , 10.15 major isomer and 9.91 minor isomer 1H, d, J 7Hz,CHO .Preparation 16 p Nitrobenzyl 5R, 6R0 3 Z 3 hydroxy 1 methyl prop 1enylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate The mixture of p nitrobenzyl 5R,6R 3 Z 3 oxol methylprop l enylthsol 6 S l trlmethylsllyloxyethyl 7 oxo 1 zabicyclo 3.2.0 hept 2 ene 2carboxylate and its E isomer 0.090 gm was dissolved in tetrahydrofuran 10 ml and cooled to 400C. A solution of sodium borohydride 0.021 gm in 20 aqueous tetrahydrofuran 10 ml was added and stirring was continued at this temperature for 15 minutes. The solution was then partitioned between ethyl acetate and water. The organic layer was washed with brine, dried over anhydrous magnesium sulphate and evaporated at reduced pressure. The residual gum was chromatographed over silica gel 10 gm .Elution with a gradient of 25 50 EtOAc hexane afforded the pure p nitrobenzyl 5R, 6R 3 Z 3 hydroxy 2 methylprop 1 enylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 0.045 gm as a colourless oil, max CHCl3 1786, 1709, 1612, 1558, 1522 and 848cm 1, max EtOH 316, 267 nm, H CDCl3 0.11 9H, s, Me3Si , 1.32 3H, d, J 6.5 Hz, CH3CH , 1.81 1H, broad res., OH , 2.13 3H, d, J 1Hz, CH3C C , 2.87 1H, dd, J 10Hz and 18Hz, 4 Ha , 3.45 3.65 2H, dd t,J 9Hz, 18Hz and 6Hz, 4 Hb 6 H , 4.20 4.32 2H, m, 5 H 8 H , 4.36 2H, dd, J 7Hz and ca. 1Hz, C CCH2 , 5.27 and 5.51 2H, 2xd, J 14.5Hz, CH2Ar 6.21 1H, dt, J 1.5 and 6.5Hz, C CH , 7.67 and 8.22 4H, 2xd, aromatic protons ,Preparation 17 p Nitrobenzyl 5R, 6R0 3 Z 3 azido 1 methylprop 1enylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate p Nitrobenzyl 5R, 6R 3 Z 3 hydroxy 1 methylprop 1 enylthio 6 S 1 trimethylsilyloxyethyl 7oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate 0.045 gm was dissolved in dry tetrahydrofuran 20 ml and cooled to 0 C with triphenylphosphine 0.047 gm .Hydrazoic acid 1.7M solution in toluene, 0.21 ml was added followed by dllsopropylazodlcarboxylate 0.036 gm . Stirring was continued for 15 minutes at room temperature. Ethyl acetate was then added and the organic solution was washed with dilute sodium bicarbonate solution, brine and dried over anhydrous magnesium sulphate. Removal of the solvent at reduced pressure afforded an oil, which was chromatographed over silica gel 8 gm . Elution with 25 ethyl acetate hexane afforded the title compound as a colurless oil 0.022 gm ,max CHC13 2100, 1780, 1703, 1608, 1558, 1521 and 841 cm 1, max EtOH 315, 266 nm, H CDC13 0.11 9H, s, Me3Si , 1.32 3H, d,J 6.5Hz, CH3CH , 2.18 3H, d, J 1Hz, CH3C C , 2.84 1H, dd, J 10Hz and 18Hz, 4 Ha , 3.58 1H, dd, J 9Hz and 18Hz, 4 Hb , 3.60 1H, t, J 7Hz, 6 H , 4.09 2H, m,CH2N3 , 4.2 4.35 2H, m, 5 H 8 H , 5.27 and 5.52 2H, 2 x d, J 14Hz, CH2Ar , 6.10 1H, dt, J 1Hz and 7 1Hz, C CH , 7.67 and 8.21 4H, 2 x d, J 9Hz, aromatic protons . Example 8 5R,6R 3 Z 3 amlno l methylprop l enylthlo 6 leS 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid The title compound was prepared as an aqueous solution by hydrogenolysis of p nitrobenzyl 5R,6R 3 Z 3 azldo l methylprop l enylthlo 6 S l trl methylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate, following the procedure outlined in example 1, max H20 297 nm.Preparation 18 p Nltrobenzyl 5Rt6R 3 3 oxo l phenylpro l enylthlo 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate Using the methodology of Preparation 7, p Nitro benzyl 5R,6R 3 E 2 acetamidoethenylthlo 6 S l hydroxyethyl 7 oxo 1 azablcyclot3.2.olhept 2 ene 2 carboxylate 0.3 g was treated successively with Nbromoacetamide 0.093 g and 3 phenylprop 2 ynal 0.131 g to afford the title aldehyde 0.155 g as a mixture ca. 2 5 1 of Z and E ismoers D max CH2Cl2 3600, 1790, 1725 and 1670 cm 1 CDCl3 Z isomer, 1.28 3H, d, J 6.5 Hz, MeCH , 1.47 1H, d, OH , 2.48 1H, dd, J 19 and 10.5 Hz, 4 CHa , 3.03 lH, dd, J 19 and 9Hz, 4 CHb , 3.45 1H, dd, J 6 and 8.5 Hz, 6 CH , 3.85 1H, m, CHMe , 4.00 1H, m, 5 CH , 5.31 and 5.56 each 1H, d, J 13.5Hz, CH2Ar , 6.65 1H, d, J 7.5Hz, CH , 7.48 5H, m, Ph , 7.66 and 8.28 each 2H, m, ArCH2 and 10.30 1H, d, J 7.5Hz, CHO E isomer, 1.33 3H, d, J 6.5 Hz, MeCH , 1.72 1H, d, OH , 2.77 1H, dd, J 19 and 10.5Hz, 4 CHa , 3.23 1H, dd, J 9 and 19Hz, 4 CHb , 3.54 1H, dd, J 6 and 8.5Hz, 6 CH , 4.00 1H, m, CHMe , 4.14 1H, m, 5 CH , 5.28 and 5.53 each 1H, d, J 13.5Hz, CH2Ar , 6.42 1H, d, J 7.5Hz, CH , 7.65 5H, m, Ph , 7.65 and 8.25 each 2H, m, ArCH2 and 9.38 1H, d, J 7.5Hz, CHO .Preparation 19 p Nltrobenzyl 5R,6R 3 3 hydroxy l phenylprop l en l ylthio 6 S 1 timethylsilyloxyethyl 7 oxo 1azabicyclo 3.2.0 hept 1 ene 2 carboxylate p Nitrobenzyl 5R, 6R0 3 3 oxo 1 phenylprop 1 enylthlol 6 S l hydroxyethyl 7 oxo l azablcyclo 3.2.0 hept 2 ene 2 carboxylate 0.133 9 was treated with trimethylsilyl chloride 0.1 ml in pyridine 5 ml in the manner described in Preparation 1. After work up the crude product was dissolved in tetrahydrofuran, and the solution treated with sodium borohydride 28 mg as in Preparation 16. After work up, the crude product was chromatographed using 30 hexane in ethyl acetate as eluant to afford the title alcohol 101 mg Z isomer E isomer ca. 2 1 max EtOH 321 and 254 nm max CH2C12 3610, 1790 and 1705 cm 1 CDCl3 , Z isomer, 0.03 9H, s, Me3Sl , 1.24 3H, d, J 6.5Hz, MeCH , 1.64 1H, br, OH , 2.57 1H, dd, J18 and 10Hz, 4 CHa , 3.12 1H, dd, 3 18 and 9Hz, 4 CHb , 3.48 1H, dd, J 6 and 7.5Hz, 6 CH , 4.02 2H, m, 5 CH and CHMe , 4.62 2H, m, H2CH , 5.28 and 5.56 each 1H, d, J 13.5Hz, ArCH2 , 6.62 1H, t, J 6Hz, CH , 7.37 5H, m, Ph , 7.67 and 8.23 each 2H, d,J 9Hz, ArCH2 E isomer similar except 0.06 9H, s,Me3Si , 2.62 1H, 4 CHa , 3.17 1H, 4 Chb , 3.46 6 CH , 4.27 2H, d, J 6.5Hz, CH.CH2 , 7.58 5H, Ph , 7.65 and 8.22 each 2H, ArCH2 . Preparation 20 p Nltrobenzyl 5R16R 3 3 azido 1 phenylprop l enyl thio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate p Nitrobenzyl 5R, 6R 3 3 hydroxy 1 phenylprop 1enylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azablcyclo 3.2.0 hept 2 ene 2 carboxylate 85 mg was treated with triphenylphosphine 90 mg , di isopropyl azodicarboxylate 69 mg and hydrazoic acid 0.1 ml of a 1.7M solution in toluene in the manner described inPreparation 17.Chromatography of the crude product using 25 35 ethylacetate in hexane to elute gave the title azido derivative as a clear oil 41 mg Z E isomers ca. 2.5 1 max EtON 321 and 56 nm max CH2C12 2100, 1785 and 1710 cm 1 S CDC13 Z isomer, 0.03 9H, s, Me3Sl , 1.22 3H, d, J 6.5Hz,MeCH , 2.52 1H, dd, J 10 and 18 Hz, 4 CHa , 3.12 1H, dd, J 9 and 18 Hz, 4 CHb , 3.47 1H, dd, J 6 and 7.5Hz, 6 CH , 4.02 2H, m, 5 CH and CHMe , 4.24 1H, dd, J 6.5 and 14.5 Hz, CHCHa , 4.37 1H, dd, J 7.5 and 14.5 Hz, Ch.CHb , 5.29 and 5.57 each 1H, d, J 14Hz, CH2Ar , 6.46 1H, t, J 7Hz, CHCH2 , 7.40 5H, m, Ph , 7.68 and 8.24 each 2H, d, J 9Hz, ArCH2 E isomer similar except 0.06 9H, s, Me3Si , 1.24 3H, d, MeCH , 2.62 1H, 4 CHa , 3.23 1H, 4 CHb , 3.48 1H, 6 CH , ca. 4.0 2H, m, CHCH2 , 5.26 and 5.52, 2H, CH2Ar , 6.44 1H, CH , 7.58 5H, Ph , 7.67 and 8.22 each 2H,ArCH2 . Example 9 5R, 6R 3 3 Amino 1 phenylprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid The title amino acid as mixture ca. 2.5 1 of Z and E isomers was prepared in aqueous solution by hydrogenolysis of 2 nltrobenzyl 5R, 6R 3 3 azido l phenylprop l enylthlo 6 S l trlmethylsllyloxy ethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 car boxylate following the procedure outlined in example 1, except that the hydrogenation period was extended to 2.75h. The product possessed an absorption at max H2O 301 nm in the u.v. spectrum. Preparation 21 p Nitrobenzyl 5R,6S 3 C Z 3 oxo l methylprop l enylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate The title compound was prepared from p nitrobenzyl 5R, 6S 3 E 2 acetamidovinylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate by the procedure described in preparation 14, max CHCl3 3400, 1782, 1720, 1678, 1608 cm max EtOH 319, 263 nm 6H CDCl3 1.36 3H, d, J 6.3 Hz, CH3CH , 2.30 3H, s, vinylic CH3 , 3.02 1H, dd, J 9 and 18 Hz, 4 Ha 3.17 1H, dd, J 9.75 and 18 Hz, 4 Hb , 3.25 1H, dd, J 6.5 and 2.9 Hz, 6 H , 4.2 4.4 2H, m, 5 H and 8 H , 5.27 1H, d and 5.52 1H, d CH2Ar , 6.37 1H, dd, J 1.25 Hz and 7 Hz, CH C , 7.67 2H, d, aromatic , 8.23 2H, d, aromatic , 10.10 1H, d, J 7 Hz, CHO m e 432.0995 M , C20H20N2O7S requires 1432.0991 . Preparation 22 p Nitrobenzyl 5R, 6S 3 C Z 3 hydroxy l methylprop l enylthio 6 R 1 trimethylsilyloxy ethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate The title compound was prepared from p nitrobenzyl 5R, 6S0 3 Z 3 oxo 1 methylprop 1 enylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylate via p nitrobenzyl 5R, 6S 3 E Z 3 oxo i methylprop 1 enylthio 6 R 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate by the procedures described in preparations 15 and 16 v max CHCl3 1780, 1702 and 1610 cm01 max EtOH 318, 266 nm 8H CDCl3 0.16 9H, s, SiMe3 , 1.28 3H, d, J 6 Hz, CH3CH , 2.11 3H, s, vinylic CH3 , 2.96 1H, dd,J 9 and 18 Hz, 4 Ha , 3.10 1H, dd, J 9.5 and 18 Hz, 3.15 1H, dd, J 2.7 and 6.3 Hz, 6 H , 4.1 4H, m, 5 H 8 H CH2OH , 5.28 1H, d, and 5.51 1H, d Ch2Ar . 6.19 1H, dt, J 1.5 and 6.5 Hz, vinylic CH , 7.66 2H, d, aromatic , 8.22 2H, d, aromatic m e 506.1544 M , C23H30N207SSi requires 506.1543 . Preparation 23 p Nitrobenzyl 5R, 6S 3 Z 3 azido 1 methylprop 1enylthio 6 R 1 trimethylsilyl oxyethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate The title compound was prepared from p nitrobenzyl 5R, 6S 3 Z 3 hydroxy 1 methylprop 1 enylthio 6 R 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate by the procedure described in preparation 17, max CHCl3 2110, 1780, 1718, 1611 imax EtOH 318, 266 nm 6H CDCl3 0.14 9H, s, SiMe3 , 1.30 3H, d, CH3CH , 2.16 3H, s, vinylic CH3 , 2.93 1H, dd, J 9 and 18 Hz, 4 Ha , 3.03 1H, dd, J 9.5 and 18 Hz, 4 Hb , 3.15 1H, dd, J 2.8 and 6.3 Hz, 6 H , 4.0 4.3 4H, m, 5 H 8 H CH,OH , 5.25 1H, d and 5.149 1H, d , CH2Ar , 6.09 1H, dt, J 1.35 and 7 Hz, vinylic CH , 7.66 2H, d, aromatic 8.21 2H, d, aromatic . Example 10 5R, 6S0 3 Z 3 amino 1 methylprop 1 enylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylic acid The title compound was prepared as an aqueous solution by hydrogenolysis of p nitrobenzyl 5R, 6S 3 Z 3 azido 1 methylprop 1 enylthio 6 R 1trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate, following the procedure outlined in example 1, Amax H2O 300 nm. Preparation 24 p Nitrobenzyl 5R, 6R0 3 E 3 oxoprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate A solution of trimethylsilyl acetylene 1.4g in dry tetrahydrofuran 30ml at 25 under Argon was treated with n butyllithium 9.2ml of a 1.55M solution in hexane . After 10 min. ethyl formate 2.3ml was added to the reaction mixture, and after a further 15 min. the reaction was quenched with saturated ammonium chloride solution 50ml . The mixture was shaken vigorously and the upper layer retained 40ml . This contained a solution of 3 trimethylsilylprop 2 yn 1 al. Using the methodology of Preparation 7, p Nitro benzyl 5R, 6R 3 E 2 acetamidoethenylthio 6 S 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylate 300mg was treated with N bromoacetamide and the product then allowed to react with the aforementioned solution of 3 trimethylsilylprop 2 yn 1 al 5ml and anhydrous potassium carbonate 46mg in DMF 10ml . Work up as described followed by chromatography on silica gel using 20 and 10 hexane in ethyl acetate for elution afforded the title aldehyde 58mg Xmax EtOH 337 and 263 nm vmax CH2Cl2 1785, 1705 and 1675 cm 6 CDCl3 1.45 3H, d, J 6.5 Hz, MeCH , 1.85 1H, d, J 4.5 Hz, OH , 3.30 1H, dd, J 18 and 10.5 Hz, 4 CHa , 3.68 1H, dd, J 6 and 8 Hz, 6 CH , 3.75 1H, dd, J 18 and 8.5 Hz, 4 CHb , 4.26 1H, m, CHMe , 4.46 1H, m, 5 CH , 5.28 and 5.51 each 1H, d, J, 13.5 Hz,CH2Ar , 6.44 1H, dd, J 7 and 15.5 Hz, CH.CH0 ,7.73 1H, d, J 15.5 Hz, CHS , 8.24 and 7.65 each 2H, d, J 13.5 Hz, Ar CH2 and 9.48 1H, d, J 7 Hz, CHO . Preparation 25 p Nitrobenzyl 5R, 6R 3 E 3 hydroxyprop 1 enylthio 6 s 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate p itrobenzyl 5R, 6R 3 E 3 oxopop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate 55mg was treated with trimethylsilyl chloride in the manner described in Preparation 1. The product 49mg was then reduced with sodium borohydride 11mg using the methodology of Preparation 16 to afford the title alcohol 28mg Xmax EtOH 324 and 264mm Vmax CH2Cl2 3610, 1780 and 1700 cm1 6 CDCl3 0.10 9H, s, Me3Si , 1.34 3H, d, J 6.5 Hz, MeCH , 3.07 1H, dd, J 10 and 18 Hz, 4 CHa , 3.60 1H, t, J 6 Hz, 6 CH , 3.69 1H, dd, J 8.5 and 18 Hz, 4 Chb , ca. 4.3 4H, m, 5 CH, CHMe and CH2CH , 5.26 and 5.50 each 1H, d, J 14 Hz, CH2Ar , 6.21 1H, dt, J 15 and 5 Hz, CH.CH2 , 6.50 1H, dt, J 15 and 1.5 Hz, SCH , 7.66 and 8.22 each 2H, d, J 9 Hz ArCH2 , M , 492.1388 C22H28N207SSi requires 492. 1386 . Preparation 26 p Nitrobenzyl 5R, 6R 3 E 3 azidoprop 1 enylthio 6 t S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 32.o3 hept 2 ene 2 carboxylate p Nitrobenzyl 5R,6R 3 E 3 hydroxyprop 1 enylthio 6 S 1 trimethylsilyloxyethjyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate 100mg was treated with triphenylphosphine 9Omg , di isopropylazodicarboxylate 69mg and hydrazoic acid 0.1 ml of a 1.7M solution in toluene using the methodology ofPreparation 17.The title azido derivative was obtained as an oil 62mg Xmax EtOH 321 and 263nm max CH2Cl 2010, 1785 and 1705 cm 6 CDCl3 0.10 9H, s, Me3Si , 1.34 3H, d, J 6 Hz, MeCH , 3.07 1H, dd, J 10.5 and 18 Hz, 4 CHa , 3.61 1H, t, J 6 Hz, 6 CH , 3.73 1H, dd, J 8.5 and 18 Hz, 4 CHb , 3.90 2H, d, J 5.5 Hz, CHCH2 , 4.31 2H, m, 5 CH and CHMe , 5.27 and 5.50 each 1H, d, J 14, CH2Ar , 6.09 1H, dt, J 6 and 15 Hz, CHCH2 , 6.54 1H, d, J 15Hz, SCH , 7.66 and 8.22 each 2H, d, J 8.5 Hz, C6H4.NO2 . Example 11 5R, 6R 3 E 3 aminoprop 1 enylthio 6 S 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid The process described in Example 1 was employed to convert p nitrobenzyl 5R,6R 3 E E 3 azidoprop 1 enylthio 6 S 1 hydroxyethyl3 7 oxo 1 azabicyclo t3.2.0 hept 2 ene 2 carboxylate into the title amino acid Amax H20 301nm. Preparation 27 p Nitrobenzyl 5R, 6S 3 E 3 oxoprop 1 enylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate p Nitrobenzyl 5R, 6S 3 E 2 acetamidoethenylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate 1g was treated with N bromoacetamide and the resulting product with 3 trimethylsilylprop 2yn 1 al in an analogous way to Preparation 24.The title aldehyde was obtained as a solid 331mg which was crystallised from hexane ethyl acetate m.p. 138 140 C Xmax MeCN 337 e27,250 and 265 nm 14,367 max KBr 1780, 1720, 1710sh and 1665 cm CDCl3 DMF d7 1.42 3H, d, J 6.5 Hz, MeCH , 3.55 1H, dd, J 18 and 8.5 Hz, 4 CHa , 3.72 1H, dd, J 18 and 10 Hz, 4 Chb , 3.83 1H, dd, J 3 and 6 Hz, 6 CH , 4.40 1H, m, 5 CH , 5.35 and 5.56 each 1H, d, J 14 Hz, OH Ar , ca. 5.38 1H, m, CH Me , 6.41 1H, dd, J 15.5 and 7.5 Hz, CHCHO , 7.77 and 8.214 each 2H, d, J 8.5 Hz, Ar CH2 , 8.20 1H, s, OCHO , 8.23 1H, dd, J 15.5 Hz, SCH and 9.54 1H, d, J 7.5 Hz, CHO . Preparation 28 p Nitrobenzyl 5R, 6S 3 E 3 hydroxyprop 1 enylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept2 ene 2 carboxylate The method of Preparation 16 was used to convert p Nitrobenzyl 5R, 6S 3 E 3 oxoprop 1 enylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate 256mg into the title alcohol 117mg max EtOH 324 and 262 nm max CH2Cl2 3610, 1785, 1725 and 1710 sh cm 1 CDCl3 1.45 3H, d, J 6.5 Hz,MeCH , 1.68 1H, br, OH , 3.11 1H, dd, J 18 and 8.5 Hz, 4 CHa , 3.34 1H, dd, J 18 and 10 Hz, CHb , 3.37 1H, dd, J 2.5 and 7 Hz, 6 CH , 4.23 3H, m, 5 CH and CH2OH , 5.26 and 5.50 each 2H, d, J 14 Hz, CH2Ar , 5.40 1H, m, CHMe , 6.22 1H, dt, J 15 and 4.5 Hz, CHCH2 , 6.47 1H, dt, J 15 and 1.5 Hz, SCH , 7.65 and 8.23 each 2H, d,J 9 Hz, ArCH2 and 8.05 1H, s, OCHO . Preparation 29 p Nitrobenzyl 5R, 6S 3 E 3 azidoprop 1 enylthio 6 R 1 formloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2ene 2 carboxylate p Nitrobenzyl 5R, 6S 3 E 3 hydroxyprop 1 enylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyelo t3.2.0 hept 2 ene 2 carboxylate 105mg was reacted with hydrazoic acid under the conditions of Preparation 17 to afford the title azide 73mg max EtOH 323 and 262 nm max CH2Cl2 2110, 1790, 1725 and 1705 sh cm 1 6 ODCl3 1.46 3H, d, J 6.5 Hz, MeCH , 3.12 1H, dd, J 8.5 and 18 Hz, 4 CHa , 3.34 1H, dd, J 10 and 18 Hz, 4 CHb , 3.39 1H, dd, J 3 and 7.5 Hz, 6 CH , 3.91 2H, dd, J 1 and 6 Hz, CH2N3 , 4.24 1H, m, 5 CH , 5.27 and 5.51 each 1H, d, J 13.5 Hz, CH2Ar , 5.111 1H, m, CHMe , 6.10 1H, dt, J 6 and 15 Hz, CHCH2 , 6.50 1H, dt, J 1.5 and 15 Hz, SCH , 8.06 1H, s, OCHO , 7.65 and 8.23 each 2H, d, J 9 Hz, ArCH2 . Example 12 5R, 6S 3 E 3 aminoprop 1 enylthio 6 R 1hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2carboxylic acid p Nitrobenzyl 5R, 6S 3 E 3 azidoprop I enylthio 6 R 1 formyloxyethyl 7 oxo 1 azabicyclo t3.2.0 hept 2 ene 2 carboxylate 40mg was shaken with a prehydrogenated 30 min mixture of 5 Pd C 60mg 1, 24 dioxan 20 ml , 0.05M pH 7 phosphate buffer solution 5ml and water 5ml for 2 h. The solution was filtered through Celite and the filtrate washed with three portions of ethyl acetate 30 ml . The aqueous solution was adjusted to pH 8.5 with 0.1N NaOH solution and warmed to 37 C. The pH was kept at 8.5 for 2 h. by the addition of further quantities of NaOH as necessary. After neutralising the solution to pH 7 with 0.1N HCl, it was concentrated in vacuo to small volume and loaded onto a column of Diaion HP 20. Elution with water, followed by 5 ethanol water afforded the title aminoacid, imax H20 303 nm. Preparation 30Ethyl Z 3 Triphenylmethylthiopropenoate Triphenylmethyl mercaptan 1.0 g in DMF 10ml was treated with aqueous 1N KOH 0.2ml . Ethyl propiolate 360mg in DMF 4ml was added. After 15 minutes the solution was neutralised by the addition of aqueous HCl.The solvents were removed by evaporation in vacuo. The residual gum was taken up in ethyl acetate 50ml and washed with H20 3 x 50ml , followed by brine 50ml . After drying MgSO4 the ethyl acetate was removed by evaporation in vacuo. Crystallisation of the residue from ethyl acetate hexane gave pure ethyl Z 3triphenylmethylthiopropenoate 650mg , m.p. 148 1500, max CH2Cl2 1695, 1570, 1490, 1445, 1375 and 1355 cm 1 6 90 MHz CDCl3 1.25 3H, t, J ca. 6 Hz , 4.08 2H, q,J ca. 6 Hz , 5.68 1H, d, J ca. 10 Hz , 6.73 1H, d, J ca. 10 Hz , 7.25 15H, m p.p.m. Found C, 76.71 H, 6.07 . C24H2202S requires C, 77.00 H, 5.88 . Preparation 31 Z 3 Triphenylmethylthioprop 2 en 1 ol Ethyl Z 3 triphenylmethylthiopropenoate 2.9g in dry THF 150ml was cooled in an ice bath and, under an argon atmosphere, treated with a 25 solution of diisobutylaluminium hydride in toluene 15ml and the mixture was stirred for 2 hours. Water 10ml ethanol 10ml were added, and after stirring for 3 minutes ethyl acetate 400ml and water 200ml and saturated brine solutions 100ml were added. After filtration through Celite and separation of the layers the ethyl acetate layer was washed with brine. The combined aqueous layers were extracted with ethyl acetate, and this extract was washed with brine, and combined with the other ethyl acetate extract, dried MgSO4 and evaporated in vacuo to leave an oil.This was redissolved in ethyl acetate ca. 30ml , treated with hexane ca. 80ml and placed in a refrigerator. This gave crystals of Z 3 triphenylmethylthioprop 2 en 1 ol 1.12g m.p. 143 1460, max CH2C12 3610, 1600, 1490, 1445, 1035, 1010 cm , 6 60 MHz, ODOl3 1.60 1H, s, exch. D2O , 4.23 2H, d, J ca. 5.5 Hz , 5.35 2H, m , 7.2 15H, m p.p.m., Found C, 79.21 H, 6.05 .C22H2005 requires C, 79.52 H, 6.02 . Preparation 32 Z 3 Triphenylmethylthioprop 2 en 1 ylazide Z 3 Triphenylmethylthioprop 2 en 1 ol 1.06 g inTHF 50ml was treated with triphenylphosphine 1.67g , followed by hydrazoic acid in toluene 1.7M, 7.5ml . The mixture was cooled to 00 and treated with diisopropyl azodicarboxylate 1.23ml 1.29g in THF 5ml . After 30 minutes ethyl acetate 100ml , aqueous NaHCO3 50ml and brine 50ml were added. After separation the aqueous layer was extracted with ethyl acetate. The combined ethyl acetate layers were washed with brine, dried MgSO4 and evaporated in vacuo. The product was chromatographed on silica gel 4.0 x 18cm , loading in toluene 30ml , and eluting with ethyl acetate hexane 5 95.Early fractions contained the product, evaporation in vacuo and addition of hexane gave crystals of the title compound 556mg , m.p. 94 950 vmax CH2Cl2 2110, 1600, 1495 and 1445 cm 1, 6 CDCl3, 90 MHz , 3.92 2H, d, J ca. 7 Hz , 5.50 1H, dt, J 6.6 and 9.5 Hz , 5.94 1H, d, J ca. 9 Hz , 7.25 15H, broad s . Found C, 74.30 H, 5.58 N, 11.37 S, 8.93 .C22H19N3S requires C, 73.95 H, 5.32 N, 11.76 S, 8.96 . Evaporation of the mother liquoursgave a further crop of crystals of the title compound 493mg . Preparation 33 Z 3 2 Nitrobenzyloxyearbonylamino 1 triphenylmethyl thioprop 1 eneMETHOD A Z 3 Triphenylmethylthioprop 2 en 1 ylazide 980mg in toluene 5ml was treated with triphenylphosphine 791mg in toluene 7ml and the mixture was heated at 700 under an atmosphere of argon. When evolution of nitrogen had ceased ca. 20 min the solution was cooled in an ice bath and treated with p nitrobenzyl chloroformate 709mg . Immediately a gummy solid precipitated. After 20 min ethyl acetate 100ml and aqueous NaHOO3 100ml were added and the mixture was shaken until all the gummy solid had dissolved. The ethyl acetate layer was washed with brie, dried and evaporated in vacuo.The residue was chromatographed on silica gel 4 x 18cm eluting with ethyl acetate hexane mixtures 1 9 400ml , 2 8 500ml , 3 7. Eventually the desired urethane was eluted. Evaporation in vacuo of the fractions containing this material gave the title compound as a gum 950mg .Crystallisation from ether gave Z 3 pnitrobenzyloxycarbonylamino 1 triphenylmethylprop 1 ene, m.p. 139 1400, max CH2Cl2 3430, 1725, 1605, 1510, 1350, 1225 cm 1, CDCl3. 60 MHz 3.90 2H, t, J ca. 6Hz , 4.85 1H, broad s , 5.16 2H, s , 5.35 5.65 1H, m , 5.85 1H, d, J ca. 9 Hz , 7.25 15H, m , 7.45 2H, d, J ca. 9 Hz , 8.15 2H, d, J ca. 9 Hz p.p.m.,Found C, 70.60 H, 5.40 N, 5.52 S, 6.03 .C30H26N2O4S requires C, 70.59 H, 5.10 N, 5.49 S, 6.29 . METHOD B Z 3 Triphenylmethylthioprop 2 en 1 ylazide 110mg in dry THF 3ml was treated with triphenylphosphine 81mug in dry THF lml . The solution was warmed to reflux for 15 min and then allowed to stand at ambient temperature for 1 hr. Water 0.008ml was then added, and after 1 hr more water 0.024ml was added and the mixture was heated under reflux for 30 min. The solvents were removed by evaporation in vacuo to give the crude amino compound. This was taken up in dichloromethane and treated with triethylamine 38mg , followed by p nitrobenzyl chloroformate 85mg . After 30 min the solution was washed with water, and then with brine. After drying MgS04 the CH2Cl2 was evaporated in vacuo and chromatographed on silica gel eluting with ethyl acetate hexane mixture to give the title compound 85mg . tion 34 Silver Z 3 p Nitrobenzloxycarbonylamino prop 1 en 1 ylthiolate Z 3 p Nitrobenzyloxycarbonylamino 1 triphenylmethylthioprop 1 ene 340mg in warm methanol 30ml was heated at 40 under argon and treated with silver nitrate 113mg followed by pyridine 52mg . The mixture was stirred at 400 for 1.5 h, then allowed to cool to ambient and stirred for a further 0.5 h. The solid was isolated by centrifugation, washed with methanol 2 x 30ml , followed by ether 2 x 30ml .The resultant solid was dried in a vacuum desiccator to give the title silver salt 221mg , max KBr 3400, 1700, 1605, 1515, 1385, 1345 and 1250 cm 1. Yreparation 35 Z l Acetylthio 3 P Nitrobenzyloxyearbonylaminoprop 1 ene Silver Z 3 p nitrobenzyloxycarbonylaminoprop 1ene 877mg was dissolved in warm DMF 10ml and acetonitrile 10ml was then added and, after cooling to ambient temperature, pyridine 0.3ml followed by acetyl chloride 0.2ml was added. After 10 minutes the mixture was filtered through Celite and the solvents removed by evaporation in vacuo. Ethyl acetate and water were added, the layers separated and the ethyl acetate layer was washed with water 2x followed by brine, then dried MgSO4 and evaporated in vacuo.Chromatography on silica gel 0.040 0.063 mm 230 1400 mesh ASTM 3.0 x 12 cm , eluting with ethyl acetate hexane mixtures 2 8 200ml , 3 7 200 ml , 4 6 gave the desired product. Crystallisation from ethyl acetate hexane gave Z 1 acetylthio 3 p nitrobenzyloxycarbonylaminoprop 1 ene 510mg , m.p. 107 1090, max CH2Cl2 3425, 1720, 1700, 1600, 1510, 1345, 1220, 1100 cm 1, 6 CDCl3, 60 MHz 2.39 3H, s , 3.83 2H, approx t, J ca. 6 Hz , 5.15 2H, centre of ABq , 5.5 6.0 1H, m , 6.60 1H, d, J ca.9 Hz , 7.45 2H, d, J ca. 9 Hz , 8.10 2H, d, J ca. 9 Hz ,Found C, 50.16 H, 4.55 N, 8.96 S, 10.145 . C13H14N2O5S requires C, 50.32 H, 4.52 N, 9.03 S, 10.32 . Preparation 36 p itrobenzyl 5Rs, 6SR 6 1RS 1 p Nitrobenzyloxy earbonyloxyethyl 3 t Z 3 p nitrobenzyloxyearbonyl aminoprop 1 en 1 ylthio 7 oxo 1 azabicyclo 3.2.0 hept2 ene 2 carboxylate Z 1 Acetylthio 3 p nitrobenzyloxycarbonylaminoprop 1 ene 211mg in dioxan 10ml was treated with 1M NaOH aq. 1.36ml . The solution was allowed to stir at ambient temperature for 20 min. Water 5ml was added and the mixture was evaporated in vacuo to ca. 5ml.A further 5ml of water was added and the mixture was stirred and cooled in an ice bath. p Nitrobenzyl 5RS, 6SR 6 1RS 1 p nitrobenzyloxyearbonyloxyethyl 3 2 pyrimid inylRulphinyl 7 oxo 1 azabicyclo 3.2.03hept 2 ene 2 carboxylate 393mg and benzyldimethyl n hexadecylammonium chloride 25mg in dichloromethane 10ml were added and the mixture was stirred rapidly for 4 minutes. The layers were separated and the dichloromethane was washed with water, then with brine, then dried MgSO4 and evaporated in vacuo. The residue was chromatographed on silica gel 3.0 x 16cm eluting with ethyl acetate hexane mixtures 1 1 250ml , 6 4 250ml , 65 35 250ml , 7 3.Fractions containing the title compound were combined and evaporated in vacuo to give the title compound 320mg max CHSCl2 3440, 1775, 1745 sh , 173a, 1700 sh , 1525, 1350 cm 1, 6 CDCl3, 250 MHz , 1.49 3H, d, J, 6.3 Hz , 3.08 1H, dd, J 17.9 and 8.5 Hz , 3.27 1H, dd, J 18.1 and 9.9 Hz , 3.39 1H, dd, J 7.9 and 2.7 Hz , 4.01 2H, t, J 6.2 Hz , 4.23 1H, m , 5.03 1H, broad,NH , ca. 5.15 1H, m , 5.19 5.3 5H, m , 5.50 1H, d,J 13.8 Hz , 5.98 1H, m , 6.33 1H, d, J 9.5 Hz , 7.50 2H, d, J 8.5 Hz , 7.59 2H, d, J 8.8 Hz , 7.65 2H, d,J 8.7 Hz , 8.2 8.3 6H, m p.p.m. Preparation 37Silver Z 3 Azidoprop 1 en 1 ylthiolate Z 3 Azido 1 triphenylmethylthioprop 1 ene 714mg in warm methanol 15ml was heated at 40 under argon and pyridine 166mg followed by finely ground silver nitrate 340mg were added. The mixture was stirred at room temperature for 2 hr. The brown precipitate was collected by filtration and was washed with methanol 6 x 10ml followed by ether 2 x 30ml . The resultant solid was dried in a vacuum desiccator to give the title silver salt 351mg which was used immediately in Preparation 38. Preparation 38 p Nitrobenzyl 5RS, 6SR 6 1RS 1 p nitrobenzyloxy carbonyloxyethyl 3 Z 3 azidoprop 1 en 1 ylthio3 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate p Nitrobenzyl 5RS, 6SR 6 1RS 1 p nitrobenzyloxycarbonyloxyethyl 3 2 pyrimidinylsulphinyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate 61mg was dissolved in acetonitrile 5ml and the mixture was cooled in an ice bath. Sodium iodide 143mg followed by silver Z 3 azidoprop 1 en 1 ylthiolate 100mg were added and the mixture stirred for 10 minutes. The solid was removed by centrifugation and the precipitate washed with dichloromethane 2 x 10ml . The dichloromethane and acetonitrile solutions were combined and evaporated under reduced pressure to give a yellow solid. This solid was suspended in dichloromethane 10ml and centrifuged.The procedure was repeated x3 and the dichloromethane layers which were removed on each occasion were combined and evaporated in vacuo to give an oil which was chromatographed on silica gel eluting with ethyl acetate hexane solvent mixture 1 1 . The fractions containing the title compound were combined and evaporated in vacuo to give the title compound 16mg Xmax EtOH 322.3 nm and 260.5 nm max CH2C12 2930, 2100, 1785, 1750, 1705, 1610, 1560, 1525, 1380, 1350, 1335, 1245, 1200, 1140, 1035 and 850 cm 1 CDCl3, 250 MHz 1.49 3H, d, J 6.4 Hz , 3.10 1H, dd, J 18.1 and 8.4 Hz , 3.31 1H, dd J 18.0 and 9.8 Hz , 3.41 1H, dd, J 7.9 and 2.9 Hz , 4.02 2H, m , 4.25 1H, m , ca.5.16 1H, m , 5.25 2H,s , 5.27 1H, d, J 13.7 Hz , 5.51 1H, d, J 13.7 Hz , 6.01 1H, dt, J 7.0 and 9.4 Hz , 6.50 1H, d, J 9.4 Hz , 7.54 2H, d, J 8.8 Hz , 7.64 2H,d,J8.7 Hz , 8.22 2H, d,J 8.7 Hz and 8.23 2H, d, J 8.8 Hz . Example 13 5RS, 6SR 3 Z 3 Aminoprop 1 enylthio 6 1RS 1 hydroxyethyl3 7 oxo 1 azabicyclop3.2.03hept 2 ene 2 carboxylic acid METHOD A 5 Pd C catalyst 300mg in dioxan 80m1 water 20m1 0.05M pH 7 potassium phosphate buffer 20m1 was prehydrogenated for 20 min. p Nitrobenzyl 5RS, 6SR 6 1RS 1 p nitrobenzyloxyearbonyloxyethyl3 3 E Z 3 P nitrobenzloxycarbonylaminoprop 1 en 1 ylthio 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate 200mg was added and the mixture was hydrogenated at atmospheric pressure for 1.5 hours. The catalyst was removed by filtration through Celite, and the Celite was washed with water 40ml . The solution was evaporated in vacuo to ca. 100 ml and washed with ethylacetate 2x .The aqueous layer was evaporated in vacuo to ca. 50ml. Chromatography of half of this solution on Diaion HP 20 2.3 x 15cm eluting with water gave the purified title compound in later fractions. These were combined and freeze dried to give the title compound.METHOD B 5 Pd C catalyst 7.0mg in dioxan 2ml water 0.5ml 0.05M pH 7.0 potassium phosphate buffer 1ml was prehydrogenated for 45 minutes. p Nitrobenzyl 5RS, 6SR 6 1RS 1 p nitrobenzyloxycarbonyloxyethyl 3 Z 3 azidoprop 1 en 1 ylthio 7 oxo 1 azabicyclo t3.2.0 hept 2 ene 2 earboxylate 5mg was added and the mixture was hydrogenated at atmospheric pressure for 1.5 hours. The catalyst was removed by filtration through Celite and the Celite was washed with water 20ml . The solution was evaporated in vacuo to ca. 10m1 and washed with ethyl acetate 3x . The aqueous layer was evaporated in vacuo to 3ml to give a solution of the title compound, max H20 297.7 nm. Preparation 39Methyl Z 3 triphenylmethylthiobut 2 enoate Triphenylmethylmercaptan 28.15gm and methyl tetrolate 10gm were dissolved in N,N dimethylformamide 125ml . 1M Potassiiirn hydroxide solution lml was added and the resulting solution was stirred at room temperature for 1 hour. The solution was then neutralised by the addition of 1M hydrochloric acid solution lml and evaporated at reduced pressure, The residual oil was partitioned between ethyl acetate and water.The organic layer was separated and washed with water x3 , brine and dried MgSO4 . Evaporation of the organic solution at reduced pressure gave an orange oil, which was chromatographed over silica gel. Elution with a gradient of hexane to 10 ethyl acetate hexane afforded the title compound as a white solid 15gm , max CHCl3 1688, 1570cm 1 H CDCl3 1.48 3H, s, MeC C , 3.62 3H, s, OO2Me , 5.55 3H, s, HC C , 7.20 15H,m, aromatic H . Preparation 40 Z 3 Triphenylmethylthiobut 2 en 1 ol The title compound was prepared from methyl Z 3 triphenylmethylthiobut 2 enoate by the procedure described in preparation 31, max CHCl3 3550 cm 1 H CDCl3 1.28 1H, broad s, OH , 1.62 3H, s, MeC C , 3.90 2H, d, CH2OH , 5.62 1H, t, HC C , 7.0 7.5 15H, m, aromatic H . Preparation 41 Z 3 Triphenylmethylthiobut 2 en 1 yl azide and E 3 Triphenylmethylthiobut 2 en l yl azide The inseparable mixture 2 1 of Z 3 triphenylmethylthiobut 2 en 1 yl azide and E 3 triphenylmethylthiobut 2 en 1 yl azide was prepared from Z 3 triphenylmethylthiobut 2 en 1 ol by the procedure described in preparation 32, max CHCl3 2100cm 1, 6H CDCl3 1.58 s, major and 1.68 s, minor 3H, MeC C , 3.31 d, minor and 3.60 d, major 2H, CH2N3 , 5.0 t, minor and 5.48 t, major 1H, HC C ,6.9 7 5 15H, m, aromatic H . Preparation 42 Z 1 p Nitrobenzyloxyearbonylamino 3 triphenylmethyl thiobut 2 ene and E 1 p Nitrobenzyloxycarbonylamino3 triphenylmethylthiobut 2 ene The title compounds were prepared from the mixture of Z 3 triphenylmethylthiobut 2 en 1 yl azide and E 3 triphenylmethylthiobut 2 en 1 yl azide by the procedure described in preparation 33, method A. They were separated by silica gel column chromatography, eluting with a gradient of 10 to 25 ethyl acetate hexane.The first eluted component was the major product, Z 1 p nitrobenzyloxycarbonylamino 3triphenylmethylthiobut 2 ene, Vmax CHCl3 3450, 1720, 1603cm 1 6H CDCl3 1.61 3H, s, MeC C , 3.66 2H, t,CH2N , 4.20 1H, broad res., NH , 5.11 2H, s, CH2Ar , 5.58 1H, t, HC C , 7.1 7.6 m, aromatic protons , 8.18 2H, d, aromatic protons .The second eluted component was the minor isomer, E 1 p nitrobenzyloxycarbonylamino 3 triphenylmethylthiobut 2 ene, max CH2Cl2 3440, 1722, 1602cm 1 EH CDCl3 1.62 3H, s, MeC O , 3.48 2H, t, CH2N , 4.03 1H, broad res., NH , 4.8 5.3 3H, m s, CH2Ar HC C , 7.0 7.6 m, aromatic protons , 8.18 2H, d, aromatic protons . Preparation 43Silver salt of E l E nitrobenzyloxycarbonylamino 3 mercaptobut 2 ene E 1 p nitrobenzyloxycarbonylamino 3 triphenyl methylthiobut 2 ene 500mg was dissolved in dry methanol 50ml by heating to reflux. Pyridine 0.092ml O.090gm , followed by powdered silver nitrate 0.195gm was added and the mixture was stirred at ambient temperature, under an argon atmosphere, for 3 hours.The solid was isolated by centrifugation and washed with methanol x2 and diethyl ether x2 . The resulting pale yellow solid was dried under vacuum and stored under argon , in the dark. Preparation 44 Z 1 ji Nitrobenzyloxycarbonylamino 3 formylthiobut 2 ene Z 1 p Nitrobenzyloxycarbonylamino 3 triphenyl methylthiobut 2 ene 0.500gm was dissolved in dry acetonitrile 50ml and stirred at room temperature for 3 hours, under an argon atmosphere, with pyridine 0.077ml , methanol 0.031my and powdered silver nitrate 0.162gm . To this mixture was then added acetic formic anhydride 0.839gm , 4 dimethylaminopyridine 0.105gm and triethylamine hydrochloride 1.312gm at ice bath temperature. The suspension was stirred for an additional 30 minutes at room temperature, and then filtered through Celite. The filtrate was evaporated at reduced pressure and the residue was partitioned between ethyl acetate and 5 citric acid solution.The organic layer was washed with saturated sodium chloride solution, saturated sodium bicarbonate solution, saturated sodium chloride solution again and dried over anhydrous magnesium sulphate. Evaporation of the solvent gave the crude product which was purified by rapid silica gel column chromatography 4Ogm . Elution with 25 ethyl acetate hexane gave the title compound as a white solid 0.140gm , vmax CH2Cl2 3440, 1725, 1679, 1608cm, 6H CDCl3 2.11 3H, s, CH3C C , 3.87 2H, t, CH2N , 5.20 3H, s broad res., CH2Ar NH , 6.10 1H, broad, HC C , 7.41 2H, d, aromatic protons , 8.16 2H, d, aromatic protons , 10.00 1H, s, CHO . Preparation 45 p Nitrobenzyl 5RS, 6SR 3 E 3 p nitrobenzyloxycarbonylamino 1 methylprop 1 enylthio 6 RS 1 D nitrobenzyloxyearbonyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate Reaction of the silver salt of E 1 p nitrobenzyl oxycarbonylamino 3 mercaptobut 2 ene with p nitrobenzyl 5RS, 6SR 3 2 pyrimidinylsulphinyl 6 RS 1 pnitrobenzyloxycarbonyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate by the procedure outlined in preparation 38 afforded the title compound as an oil, 9max CHCl3 3450, 1782, 1722, 1608cm 1 6H CDCl3 1.48 3H, d, J 6.5Hz, CH3CH , 2.08 3H, s,CH3C C , 3.01 1H, dd, 4 Ha , 3.13 1H, dd, 4 Hb , 3.36 1H, dd, J 2.5 and 8.0 Hz, 6 H , 3.90 2H, broad res., CH2N , 4.18 1H, dt, 5 H , 5.1 5.55 8K, m, 3 x CH2Ar 8 H NH , 6.05 1H, broad t, HC C , 7.45 7.7 m, aromatic protons , 8.21 d, aromatic protons . Example 14 5RS, 6SR 3 E 3 amio 1 methylprop 1 enylthio 6 RS 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept2 ene 2 carboxylic acid The title compound was prepared as an aqueous solution by hydrogenolysis of p nitrobenzyl 5RS, 6SR 3 E 3 p nitrobenzyloxyearbonylamino 1 methylprop 1 enylthio 6 RS 1 p nitrobenzyloxycarbonyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate, following the procedure outlined in example 13, vmax H20 299nm. In this case the hydrogenolysis time was extended to 3 hours. Preparation 46 ANitrobenzyl 5R, 6S 3 C Z 3 E nitrobenzyloxycarbony amlno 1 methylprop 1 enylthio 6 R 1 hydroxyethyl 7 oXo 1 azabicyclot3.2.0 hept 2 ene 2 carboxylate A. Z 1 p Nitrobenzyloxycarbonylamino 3 formylthio but 2 ene 0.570gm was dissolved in 1, 4 dioxan some and stirred at room temperature for 30 minutes with IN sodium hydroxide solution 3.68ml . The 1, 4 dioxan was then removed by evaporation at reduced pressure.The resulting solution was diluted with water 25ml .B. p Nitrobenzyl 5R, 6S 3 E 2 acetamidovinylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept2 ene 2 carboxylate 0.512gm was converted to its sulphoxide by established procedures. This was then dissolved in dichloromethane 10Qml and vigorously stirred for 15 minutes with the aqueous solution obtained from part A, in the presence of cetyl dimethylbenzylammonium chloride 0.051gm . The two layers were separated and the organic layer washed with water, saturated sodium chloride solution and dried MgSO4 .Removal of the solvent at reduced pressure afforded the crude product, which was purified by silica gel column chromatography 50gm . Elution with a gradient of 25 75 ethyl acetate hexane gave the title compound as a pale yellow foam 0.lOlgm , max CH2Cl2 3600, 3450, 1780, 1725, 1608 cm 1 Xmax EtOH 317, 265nm 6H ODCl3 1.35 3H, d, J 6.5 Hz, CH3CH , 1.82 1H, d, OH , 2.10 3H, d, J 1.0 Hz,CH3C C , 3.00 1H, dd, 4 Ha 3.13 1H, dd, 4 Hb , 3.20 1H, broad d, 6 H , 4.03 2H, broad res., CH2N , 4.22 2H, m, 5 H 8 H , 5.03 1H, broad t, NH , 5.20 2H, s, CH2Ar , 5.25 d and 5.52 d 2H, CH2Ar , 6.04 1H, broad t, HC C , 7.50 2H, d, aromatic , 7.67 2H, d, aromatic , 8.21 4H, d, aromatic . Example 15 5R, 6S 3 Z 3 amino 1 methylprop 1 enylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylic acid Hydrogenolysis of p nitrobenzyl 5R, 6S 3 Z 3p nitrobenzyloxycarbonylamino 1 methylprop 1 enylthio 6 R 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept2 ene 2 carboxylate, by the procedure described in example 13, gave the title compound, also described in example 10, as a white fluffy solid after Biogel P 2 column chromatography and lyophilisation, imax H20 299nm, Vmax KBr 3250, 1760cm 1. The hydrogenolysis time in this case was extended to 3 hours. Preparation 47 p Nitrobenzyl 5R, 6R0 3 E 3 hydroxy 1 methylprop 1 enylthio 6 S 1 trimethylsilyloxyethyl 7 oXo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate When Preparation 16 was performed on a sufficiently large scale, small quantities of the title compound could be isolated in pure form 12 yield on continued elution of the silica gel column, Vmax CHCl3 3420, 1780, 1705, 1611 cm max EtOH 317, 265nm 6H CDCl3 1.30 3H, d, J 6 Hz, CH3CH , 2.02 3H, s,CH3C C , 2.86 1H, dd, 4 Ha , 3.4 3.9 2H, m, 4 H a 6 H , 4.1 4.4 4H, m, CH20 5 H 8 H , 5.21 d 5.48 d 2H, CH2Ar , 6.21 1H, t, HC C , 7.64 2H, d, aromatic protons , 8.18 2H, d, aromatic protons . Preparation 48 p Nitrobenzyl 5R, 6R 3 E 3 azido 1 methylprop 1 enylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1azabicyclo 3.2.0 hept 2 ene 2 carboxylate The title compound was prepared from p nitrobenzyl 5R, 6R 3 E 3 hydroxy 1 methylprop 1 enylthio 6 S 1 trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate by the procedure outlined in preparation 17, Xmax EtOH 317, 264nm max CHCl3 2100, 1775, 1721, 1605cm 1 6H CDC13 0.12 9H, s, Me3Si , 1.33 3H, d, CH3CH , 2.12 3H, d,J ca. 1 Hz, CH3C C , 2.92 1H, dd, 4 Ha , 3.5 3.75 2H, m, 4 Hb 6 H , 3.89 2H, d, CH2N3 , 4.2 4.36 2H, m, 5 H 8 H , 5.28 d 5.51 d 2H, CH2Ar , 6.18 1H, dt, HC C , 7.66 2H, d, aromatic protons , 8.22 2H, d, aromatic protons . Example 16 5R, 6R 3 E 3 amino 1 methylprop 1 enylthio 6 S 1 hydroxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate The title compound was prepared as an aqueous solution by hydrogenolysis of p nitrobenzyl 5R, 6R 3 E 3 azido 1 methylprop 1 enylthio 6 S 1trimethylsilyloxyethyl 7 oxo 1 azabicyclo 3.2.0 hept 2 ene 2 carboxylate, following the procedure outlined in example 1, AmaX H20 298nm.In this case, the hydrogenolysis time was extended to 3 hours. Antibacterial Activity of Aminopropenyl DerivativesEMI81.1 tb SEP MIC SEP pg ml tb Compound SEP R SEP SEP E SEP col1 SEP S SEP aureus SEP S SEP typhumurium SEP P SEP aeruginosa tb of SEP Russell SEP CT10 SEP A tb Example tb SEP 1 SEP 0.4 SEP 0.1 SEP 0.2 SEP 6.2 tb SEP 2 SEP 0.3 SEP 0.08 SEP SEP 0.6 SEP 25 tb SEP 13 SEP 0.4 SEP SEP 0.08 SEP 0.6 SEP i SEP 25 tb SEP 8 SEP 1.6 SEP 0.1 SEP 0.1 SEP . SEP 25 tb SEP 10 SEP 0.2 SEP SEP 0.1 SEP 0.2 SEP 25 tb SEP 11 SEP 0.1 SEP 0.1 SEP 0.4 SEP 12.5 tb SEP 12 SEP 0.2 SEP SEP 0.1 SEP 0.2 SEP 12.5 tb SEP 16 SEP 1.6 SEP 0.1 SEP 0.2 SEP 25 tb SEP 14 SEP 0.4 SEP SEP 0.1 SEP 0.4 SEP 25 tb Racemic not corrected for presence of inactive enantiomer . Microtitre using Nutrient broth . Stability in Kidney PreparationsEMI82.1 tb SEP SEP left SEP after SEP 60 SEP minutes tb SEP Pig SEP Kldney SEP Acetone SEP Powder SEP Human SEP Kldney SEP Sonlcate SEP tb Example SEP 100 SEP mg ml SEP solubilised SEP 15 SEP solubilised SEP in tb SEP in SEP 5 SEP Triton SEP X 100 SEP 5 SEP Triton SEP X 100 tb SEP 1 SEP 39 SEP 40 tb SEP 13 SEP 40 SEP 39 tb SEP 8 SEP 78 SEP 51 tb SEP 10 SEP 77 SEP 56 tb SEP 11 SEP 6 SEP 7 tb SEP 12 SEP 8 SEP 5 tb SEP 16 SEP 38 SEP 13 tb SEP 14 SEP 36 SEP 23 tb These are racemic compounds Figures are based on stability of bio active enantiomer .